Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2S)-2-((4-[(2-amino-6-ethyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
50% inhibition at 0.00042 mM, additionally inhibitory on thymidylate synthase
(2S)-2-((4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
50% inhibition at 0.0021 mM, additionally inhibitory on thymidylate synthase
(4-(1-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]ethyl)phenyl)methanol
-
(E)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
-
DHFR binding structure, modelling, overview
(Z)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
-
DHFR binding structure, modelling, overview
1-(3-([(2,4-diaminopteridin-6-yl)methyl]amino)phenyl)ethanol
-
2,4-diamino-5-(3-phenylprop-1-ynyl)-6-ethylpyrimidine
-
-
2,4-diamino-5-isopropyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
evaluation of cytotoxicity against 17 different tumor cell lines
2,4-diamino-5-propyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
evaluation of cytotoxicity against 17 different tumor cell lines. GI values are below 100 nM
2,4-diamino-5-[3-(2,3-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-npropylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]pyrimidine
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)-3-methylbut-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(4-methoxyphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(4-tertbutylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(6-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-6-[(2',5'-dichloroanilino)methyl]pyrido[2,3-d]pyrimidine
OAAG324, a potent inhibitor of dihydrofolate reductase, analysis of the enzyme-inhibitor structure of wild-type enzyme and mutants
2,4-diamino-6-[(3',4',5'-trichloroanilino)methyl]pyrido[2,3-d]pyrimidine
-
2-(2-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)ethoxy)ethanol
-
2-amino-4-oxo-6-methyl-5-phenylsulfanylthieno[2,3-d]pyrimidine
-
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]-pyrimidin-4(3H)-one
-
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-5-[(4-fluorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-6-(4-bromophenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol
-
2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d ]pyrimidin-4(3H)-one
-
2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
-
2-amino-8-(1,3-benzodioxol-5-yl)-9-phenyl-1,9-dihydro-6H-purin-6-one
synthesis, overview
2-amino-8-(2-hydroxyphenyl)-9-phenyl-9H-purin-6-ol
-
2-amino-8-(4-methylphenyl)-9-phenyl-9H-purin-6-ol
-
2-amino-9-phenyl-8-(3,4,5-trimethoxyphenyl)-9H-purin-6-ol
-
2-amino-9-phenyl-8-[4-(propan-2-yl)phenyl]-9H-purin-6-ol
-
2-[(2-ethoxyethyl)sulfanyl]-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrilemonohydrate
-
docking score is -7.34 kcal/mol, interacts with Arg70, and Gln35, water-mediated interactions with Asn4
-
2-[(3-[3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl]prop-2-yn-1-yl)oxy]benzoic acid
ratio of IC50 values human/Trypanosoma enzyme 47
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]ethanol
-
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]-2-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethanol
-
2-[(E)-([2-amino-4-methoxy-6-(phenylamino)pyrimidin-5-yl]imino)methyl]phenol
synthesis, overview
2-[[(4-nitrophenyl)methyl]sulfanyl]-6-oxo-4-propyl-1,6-dihydropyrimidine-5-carbonitrile
-
docking score is -8.53 kcal/mol, interacts with Gln35, Asn64, and Ser59 via water, and with Val115, Phe34, Phe31
-
3-((3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy)methyl)benzoic acid
ratio of IC50 values human/Trypanosoma enzyme is 86
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
-
-
3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin
-
i.e. TMECG, synthesis of a trimethoxy derivative of epicatechin-3-gallate, which shows high antiproliferative and proapoptotic activity against melanoma. It is a prodrug that is selectively activated by the specific melanocyte enzyme tyrosinase. Upon activation, the compound generates a stable quinone methide product that strongly inhibits dihydrofolate reductase in an irreversible manner. The treatment of melanoma cells affects cellular folate transport and the gene expression of DHFR
3-[(3-(3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl)prop-2-yn-1-yl)oxy]benzoic acid
ratio of IC50 values human/Trypanosoma enzyme is 77
4-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)butanoic acid
-
4-((5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl)ethynyl)benzoic acid
ratio of IC50 values human/Trypanosoma enzyme is 129
4-(2-methylpropyl)-2-[[(4-nitrophenyl)methyl]sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carbonitrile
-
docking score is -8.34 kcal/mol, interacts with Gln35, Asn64, and Val8 via water
-
4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoic acid
-
4-(N-[(2,4-Diamino-6-pteridyl)methyl]-N-methylamino)benzoate
-
-
4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoic acid
-
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.00165 mM
5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(3-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-bromophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isobutylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isopropylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-phenylpyrimidine-2,4-diamine
-
very high Ki-value
5-(4-chlorophenyl)-6-propylpyrimidine-2,4-diamine
-
-
5-(5-[[(2,4-diamino-6-quinazolinyl)methyl](propyl)amino]-2-methoxyphenoxy) pentanoate
-
5-(methoxymethyl)-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-[(4-methoxyphenyl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(4-nitrophenyl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(naphthalen-1-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(naphthalen-2-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(quinolin-8-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[[(2-methoxy-5-methylphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(5,6,7,8-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylsulfanyl)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-2-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(pyren-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-3-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-5-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-6-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3-methylphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine
-
selective inhibition of Mycobacterium tuberculosis enzyme, little effect on human or yeast enzyme
5-[(E)-benzylideneamino]-6-methoxy-N4-phenylpyrimidine-2,4-diamine
-
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-cyclopropyl-2-(2'-methoxyphenyl)ethyl]furo-[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylbut-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-4-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)hex-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)pent-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-cyclopropyl-2-(2'-methoxyphenyl)vinyl]furo-[2,3-d]pyrimidine-2,4-diamine
-
-
5-[3-(5-methoxy-3',5'-dimethyl[1,1'-biphenyl]-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(5-methoxy[1,1'-biphenyl]-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
6-(([4-chlorotricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]amino)methyl)pteridine-2,4-diamine
-
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.00185 mM
6-([(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
-
6-([(4-aminophenyl)amino]methyl)pteridine-2,4-diamine
-
6-([(4-ethoxyphenyl)amino]methyl)pteridine-2,4-diamine
-
6-([5-quinolylamino]-methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
enzyme-bound crystal structure analysis for inhibitor screening and docking studies, PDB ID 1KMS
6-([butyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
6-([ethyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
6-([methyl(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
-
6-([methyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
6-([phenyl(prop-2-en-1-yl)amino]methyl)pteridine-2,4-diamine
-
6-([phenyl(propan-2-yl)amino]methyl)pteridine-2,4-diamine
-
6-([phenyl(propyl)amino]methyl)pteridine-2,4-diamine
-
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylamino]methyl)pteridine-2,4-diamine
-
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-ylamino]methyl)pteridine-2,4-diamine
-
6-([[2-(difluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-bromo-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-fluoro-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[3-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[4-(fluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-ethyl-5-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-[2-methoxy-5-(pyridin-4-yl)phenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
6-ethyl-5-[3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
-
6-ethyl-5-[3-[3-methoxy-5-(pyrimidin-5-yl)phenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
6-methoxy-5-[(E)-[(4-methylphenyl)methylidene]amino]-N~4~-phenylpyrimidine-2,4-diamine
-
6-methoxy-N~4~-phenyl-5-[(E)-[(pyridin-4-yl)methylidene]amino]pyrimidine-2,4-diamine
-
6-methoxy-N~4~-phenyl-5-[(E)-[[4-(trifluoromethyl)phenyl]methylidene]amino]pyrimidine-2,4-diamine
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-[(2,4-dichlorophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(2,5-dimethoxyphenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(2,6-dimethylphenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(3,4-dichlorophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(3,4-dimethoxyanilino)methyl]-2,4-quinazolinediamine
-
6-[(4-bromophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(9H-fluoren-2-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(9H-fluoren-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(anthracen-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(fluoranthen-3-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(isoquinolin-5-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(phenylamino)methyl]pteridine-2,4-diamine
-
6-[(tricyclo[4.3.0.07,9]nona-1,3,5-trien-3-ylamino)methyl]pteridine-2,4-diamine
-
6-[2-(2,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(3,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00204 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00234 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00347 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.01289 mM
6-[[(2,5-dibromophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-difluorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-ethylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dipropoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-bromo-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chloro-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-fluoro-4-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxybiphenyl-4-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-3-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-butoxy-3-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloronaphthalen-1-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-fluoro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-methoxy-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
7-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]hept-6-ynoic acid
ratio of IC50 values human/Trypanosoma enzyme is 49
epicatechin-3-O-gallate
-
-
epigallocatechin gallate
-
epigallocatechin-3-gallate
-
IC50 value around 0.1 mM
epigallocatechin-3-O-gallate
-
-
ethyl 4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoate
-
methyl 4-(2,6-diamino-5-phenylpyrimidin-4-yl)butanoate
-
-
methyl 4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoate
-
methyl 4-[(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) methyl]benzene carboxylate
-
methyl 4-[2,6-diamino-5-(3-chlorophenyl)pyrimidin-4-yl]butanoate
-
-
methyl 5-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) pentanoate
-
methylmercuric hydroxide
-
-
N-(4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
-
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl)-L-glutamic acid
dual inhibitor of both dihydrofolate reductase and thymidylate synthase. Inhibitory to Toxoplasma gondii dihydrofolate reductase, little inhibition of Escherichia coli enzyme
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
-
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl)-L-glutamic acid
binding mode, overview
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
N-(4-[[(4-amino-2-[[(2,4,6-trifluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]benzoyl)-L-glutamic acid
halogenated derivative of methotrexate, binding affinity value -34.73 kJ/mol
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)-beta-alanine
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-[1-(2-ethoxynaphthalen-1-yl)ethyl]-b-alanine
-
N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid
-
-
N-[3-[[2-[(2,4-diaminopyrimidin-5-yl)amino]ethyl](methyl)amino]prop-2-ynoyl]glutamic acid
-
N-[4-[(2,4-diamino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)sulfanyl]benzoyl]glutamic acid
-
N-[4-[(2,4-diamino-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)sulfanyl]benzoyl]glutamic acid
-
N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-2-(trifluoroacetyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.98 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-3-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.56 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-5-fluoro-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N-[4-[[(2E)-2-[(2,4-diaminopyrimidin-5-yl)imino]ethyl](methyl)amino]benzoyl]glutamic acid
-
N-[4-[[(4-amino-2-[[(2,4-difluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -36.40 kJ/mol
-
N-[4-[[(4-amino-2-[[(4-fluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, binding affinity value -34.73 kJ/mol
-
N-[4-[[2-[(2,4-diaminopyrimidin-5-yl)amino]ethyl](methyl)amino]benzoyl]glutamic acid
-
N-[4-[[[4-amino-2-([[4-(trifluoromethyl)phenyl]carbamoyl]amino)pteridin-6-yl]methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
binding complex structure analysis, the trifluorophenyl ring occupies a position near the enzyme cofactor-binding site, with close intermolecular contacts with Asp21, Ser59 and Ile60
N6-methyl-N6-(4-isopropylphenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
binding complex structure analysis
N6-methyl-N6-1-naphthylpyrido[2,3-d]pyrimidine-2,4,6-triamine
binding complex structure analysis
N6-methyl-N6-phenylpyrido[2,3-d]pyrimidine-2,4,6-triamine
-
N7-(1-(naphthalen-1-yl)ethyl)-N7-propylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(2-aminoethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(2-ethoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(2-propoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(3-ethoxypropyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(4-aminobutyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(5-aminopentyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(cyclopropylmethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(cyclopropylmethyl)-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(prop-2-en-1-yl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-benzyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-benzyl-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-butyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-cyclopropyl-N7-(1-(naphthalen-2-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-ethyl-N7-(4-methylbenzyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-ethyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-methyl-N7-(1-phenylethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-methyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-methyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-methyl-N7-[1-(quinolin-4-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-methyl-N7-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylmethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-pentyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-ethylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(2-ethoxynaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(2-ethylnaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(4-chloronaphthalen-1-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[2-(4-fluorophenyl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[2-(cyclohex-2-en-1-yl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[3-(2-methyl-4H-imidazol-4-yl)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[3-(2-methylpropoxy)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
p-hydroxymercuribenzoate
-
-
PY957
a trimethoprim analogue
quinone methide
-
essentially irreversible inhibition
TMP
structure and ligand binding conformation of TMP
[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]acetic acid
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
folate
-
-
folate
-
substrate inhibition, IC50 value around 0.02 mM
methotrexate
-
-
methotrexate
-
recombinant enzyme
methotrexate
-
dihydrofolate antagonist drug
methotrexate
-
cell line HeLa BU-25
methotrexate
-
IC50: 1.2 nM
methotrexate
50% inhibition at 0.000022 mM
methotrexate
-
60 nM, complete inhibition
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
-
nolatrexed
-
pemetrexed
-
-
pemetrexed
i.e. LY231514, 50% inhibition at 0.0066 mM
piritrexim
-
piritrexim
-
recombinant enzyme
pyrimethamine
-
-
pyrimethamine
-
recombinant enzyme
raltitrexed
-
trimethoprim
-
-
trimethoprim
-
recombinant enzyme
trimethoprim
-
IC50: 0.0825 mM
trimethoprim
-
IC50 value around 0.07 mM
trimetrexate
-
additional information
structure-based three-dimensional quantitative structure-activity relationship 3D-QSAR approach to predict the biochemical activity for inhibitors of Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase and comparison with human dihydrofolate reductase. Crystal structures of complexes of the enzyme with eight different inhibitors of the DHFR activity together with the structure in the substrate-free state have been used to validate and refine docking poses of ligands, good agreement between experimental and predicted enzyme inhibition data
-
additional information
-
structure-based three-dimensional quantitative structure-activity relationship 3D-QSAR approach to predict the biochemical activity for inhibitors of Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase and comparison with human dihydrofolate reductase. Crystal structures of complexes of the enzyme with eight different inhibitors of the DHFR activity together with the structure in the substrate-free state have been used to validate and refine docking poses of ligands, good agreement between experimental and predicted enzyme inhibition data
-
additional information
-
inhibitor design based on a trimethoprim-like scaffold, overview
-
additional information
inhibitor synthesis and molecular modelling
-
additional information
-
inhibitor synthesis and molecular modelling
-
additional information
inhibitory potencies of diverse 2,4-pteridinediamine derivates and pyrimido[4,5-d]pyrimidine-2,4-diamine derivates, molecular dynamic simulations, detailed overview
-
additional information
-
molecular docking of 2,4-diamino-5-methyl-5-deazapteridine derivatives as inhibitors to human DHFR, drug-receptor interaction study, method development and evaluation, overview
-
additional information
-
synthesis and evaluation of 2,4-diaminofuro[2,3-d]pyrimidine inhibitors, overview
-
additional information
design and synthesis of a series of bicyclic pyrido[2,3-d]pyrimidines that contain an N6-(substituted phenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine scaffold in which the substituted aniline is directly attached to the 6-position of the pyrido[2,3-d] pyrimidine ring as selective and potent inhibitors of pathogenic sources of dihydrofolate reductase (DHFR) such as Pneumocystis jirovecii, a causative agent of pneumonia in HIV/AIDS patients. Analysis of the interactions that enhance the selectivity of binding and to directly compare the binding of the most potent analogue in the series, N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine with enzyme from Homosapiens, Pneumocystis carinii, and Pneumocystis jirovecii, overview
-
additional information
-
design and synthesis of a series of bicyclic pyrido[2,3-d]pyrimidines that contain an N6-(substituted phenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine scaffold in which the substituted aniline is directly attached to the 6-position of the pyrido[2,3-d] pyrimidine ring as selective and potent inhibitors of pathogenic sources of dihydrofolate reductase (DHFR) such as Pneumocystis jirovecii, a causative agent of pneumonia in HIV/AIDS patients. Analysis of the interactions that enhance the selectivity of binding and to directly compare the binding of the most potent analogue in the series, N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine with enzyme from Homosapiens, Pneumocystis carinii, and Pneumocystis jirovecii, overview
-
additional information
development of a series of propargyl-linked antifolates that are potent inhibitors of DHFR from multiple species. One of the strengths of this series is the flexibility and versatility to target TMP-resistant species, regardless of whether that resistance occurs natively or via acquired mutations. Determination and comparison of inhibition kinetics and binding structures of human and Klebsiella enzymes with propargyl-linked antifolate inhibitors, overview
-
additional information
-
development of a series of propargyl-linked antifolates that are potent inhibitors of DHFR from multiple species. One of the strengths of this series is the flexibility and versatility to target TMP-resistant species, regardless of whether that resistance occurs natively or via acquired mutations. Determination and comparison of inhibition kinetics and binding structures of human and Klebsiella enzymes with propargyl-linked antifolate inhibitors, overview
-
additional information
quantitative structure-activity relationship study of enzyme inhibitors using 2D-QSAR and 3D-QSAR models and methods, algorithms and method development and evaluation, overview. The biological activities pf the inhibitor molecules are correctly predicted by all the quantitative activity-structure relationship models, molecular docking study. Structures of the 23 DHFR inhibitors are obtained from molecular dynamics calculations using the human DHFR as the starting structure, PDB ID 2W3M
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Acquired Immunodeficiency Syndrome
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Acquired Immunodeficiency Syndrome
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Acquired Immunodeficiency Syndrome
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Acquired Immunodeficiency Syndrome
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Acquired Immunodeficiency Syndrome
Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes (dagger) (double dagger).
Acquired Immunodeficiency Syndrome
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Acquired Immunodeficiency Syndrome
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Acquired Immunodeficiency Syndrome
Exploring novel strategies for AIDS protozoal pathogens: ?-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR.
Acquired Immunodeficiency Syndrome
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Acquired Immunodeficiency Syndrome
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Acquired Immunodeficiency Syndrome
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
Acquired Immunodeficiency Syndrome
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum.
Acquired Immunodeficiency Syndrome
Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii.
Acquired Immunodeficiency Syndrome
Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.
Acquired Immunodeficiency Syndrome
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Acquired Immunodeficiency Syndrome
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Acquired Immunodeficiency Syndrome
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Acquired Immunodeficiency Syndrome
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Acquired Immunodeficiency Syndrome
Synthesis of new 2,4-Diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrrolo[2,3-d]pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Acquired Immunodeficiency Syndrome
Wnt/?-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1.
Acquired Immunodeficiency Syndrome
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Acute Kidney Injury
Commiphora molmol protects against methotrexate-induced nephrotoxicity by up-regulating Nrf2/ARE/HO-1 signaling.
Adenocarcinoma
Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells.
Adenocarcinoma
Thy-1 antigen on normal and neoplastic rat mammary tissues: changes in location and amount of antigen during differentiation of cultured stem cells.
Adenocarcinoma
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Adenocarcinoma of Lung
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
Adenocarcinoma of Lung
TS expression predicts postoperative recurrence in adenocarcinoma of the lung.
Adenomatous Polyps
Gene-Nutrient Interaction between Folate and Dihydrofolate Reductase in Risk for Adenomatous Polyp Occurrence: A Preliminary Report.
Adenoviridae Infections
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Adenoviridae Infections
Posttranscriptional control of DHFR gene expression during adenovirus 2 infection.
Adrenoleukodystrophy
Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample.
AIDS-Related Opportunistic Infections
Exploring novel strategies for AIDS protozoal pathogens: ?-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR.
Albuminuria
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Alveolitis, Extrinsic Allergic
Absence of Thy-1 results in TGF-? induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts.
Alzheimer Disease
Molecular cloning of human cDNA with a sequence highly similar to that of the dihydrofolate reductase gene in brain libraries derived from Alzheimer's disease patients.
Alzheimer Disease
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23).
Alzheimer Disease
Regional brain cytochrome oxidase activity in beta-amyloid precursor protein transgenic mice with the Swedish mutation.
Alzheimer Disease
Thy-1 in hippocampus: normal anatomy and neuritic growth in Alzheimer's disease.
Amebiasis
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Amnesia
Inhibition of long-term memory formation in the chicken by anti chick Thy-1 antibody.
Amnesia
Inhibition of memory in the chick using a monoclonal anti-Thy-1 antibody.
Amnesia
Purified antichick Thy-1 IgG abolishes intermediate and long-term memory.
Amyloidosis
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23).
Anemia
Anemia in a line of transgenic mice carrying a mutant dihydrofolate reductase gene.
Anemia
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Anemia
Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women.
Anemia, Megaloblastic
Congenital errors of folate metabolism.
Anemia, Megaloblastic
Dihydrofolate reductase deficiency causing megaloblastic anemia in two families.
Anemia, Megaloblastic
Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.
Anemia, Megaloblastic
Dihydrofolate reductase mutations-associated megaloblastic anemia and cerebral folate deficiency.
Anemia, Megaloblastic
Drug-induced anaemias.
Anemia, Megaloblastic
Hereditary dihydrofolate reductase deficiency with megaloblastic anemia.
Anemia, Megaloblastic
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Anemia, Megaloblastic
Update and new concepts in vitamin responsive disorders of folate transport and metabolism.
Anemia, Refractory
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Anemia, Refractory, with Excess of Blasts
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Anencephaly
Impaired retinal vascular development in anencephalic human fetus.
Anencephaly
Maternal association and influence of DHFR 19?bp deletion variant predisposes foetus to anencephaly susceptibility: a family-based triad study.
Aneurysm
Targeting feed-forward signaling of TGF?/NOX4/DHFR/eNOS uncoupling/TGF? axis with anti-TGF? and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics.
Anthrax
Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.
Anthrax
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Anthrax
X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.
Aortic Aneurysm, Abdominal
Knockout of dihydrofolate reductase in mice induces hypertension and abdominal aortic aneurysm via mitochondrial dysfunction.
Aortic Aneurysm, Abdominal
Targeting MicroRNA-192-5p, a Downstream Effector of NOXs (NADPH Oxidases), Reverses Endothelial DHFR (Dihydrofolate Reductase) Deficiency to Attenuate Abdominal Aortic Aneurysm Formation.
Arthritis
Characterization of monoclonal antibodies against a human chondrocyte surface antigen.
Arthritis
Methotrexate in rheumatoid arthritis: studies with animal models.
Arthritis
Structure of macrophage migration inhibitory factor in complex with methotrexate.
Arthritis, Juvenile
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.
Arthritis, Rheumatoid
677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
Arthritis, Rheumatoid
Antifolates in rheumatoid arthritis: a hypothetical mechanism of action.
Arthritis, Rheumatoid
Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum.
Arthritis, Rheumatoid
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Arthritis, Rheumatoid
Effect of the GPI anchor of human Thy-1 on antibody recognition and function.
Arthritis, Rheumatoid
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate.
Arthritis, Rheumatoid
Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation.
Arthritis, Rheumatoid
miRNA-24 Gene Sequence, DHFR -829C-T Genotypes, and Methotrexate Response in Mexican Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].
Astrocytoma
Activated lymphoid cells in human gliomas: morphofunctional and cytochemical evidence.
Astrocytoma
Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets.
Asymptomatic Infections
Carriage of Mutant Dihydrofolate Reductase and Dihydropteroate Synthase Genes among Plasmodium falciparum Isolates Recovered from Pregnant Women with Asymptomatic Infection in Lagos, Nigeria.
Asymptomatic Infections
High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Asymptomatic Infections
Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease.
Asymptomatic Infections
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.
Ataxia
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Ataxia Telangiectasia
DHFR gene amplification in cultured skin fibroblasts of ataxia telangiectasia patients after methotrexate selection.
Ataxia Telangiectasia
Investigations into the molecular effects of single nucleotide polymorphism.
Ataxia Telangiectasia
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food.
Ataxia Telangiectasia
Radiation-induced gene amplification in rodent and human cells.
Ataxia Telangiectasia
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Atherosclerosis
Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications.
Atherosclerosis
Tetrahydrobiopterin prevents chronic ischemia-related lower urinary tract dysfunction through the maintenance of nitric oxide bioavailability.
Autoimmune Diseases
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Autoimmune Diseases
Evaluation of ototoxicity of intratympanic administration of Methotrexate in rats.
Autoimmune Diseases
Much more than you expected: The non-DHFR-mediated effects of methotrexate.
Autoimmune Diseases
Phase II trial of methotrexate in myasthenia gravis.
Autoimmune Diseases
Simple and Reliable HPLC Method for the Monitoring of Methotrexate in Osteosarcoma Patients.
Autoimmune Diseases
The keratan sulfate disaccharide Gal(6S03) beta1,4-GlcNAc(6S03) modulates interleukin 12 production by macrophages in murine Thy-1 type autoimmune disease.
Autoimmune Diseases
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
Autoimmune Diseases
Vitamin B17 Ameliorates Methotrexate-Induced Reproductive Toxicity, Oxidative Stress, and Testicular Injury in Male Rats.
Babesiosis
Inhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovis.
Bacterial Infections
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
Bacterial Infections
Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
Bacterial Infections
Dihydrofolate reductase inhibitors for use as antimicrobial agents.
Bacterial Infections
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Bacterial Infections
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Bacterial Infections
Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae.
Bacterial Infections
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Bacterial Infections
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Bacterial Infections
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Bacterial Infections
Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.
Biliary Atresia
Isolation of Hepatic Progenitor Cells From Human Liver With Cirrhosis Secondary to Biliary Atresia Using EpCAM or Thy-1 Markers.
Blast Crisis
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Blast Crisis
Histochemical demonstration of tetrahydrofolate dehydrogenase in blast crisis of chronic myeloid leukaemia.
Blister
Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors.
Bone Resorption
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
Brain Diseases
Decreased cell surface prion protein in mouse models of prion disease.
Brain Neoplasms
Dihydrofolate reductase activity in primary brain tumors in children.
Brain Neoplasms
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Brain Neoplasms
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Brain Neoplasms
Natural resistance to methotrexate in human melanomas.
Breast Neoplasms
5' Nucleotide sequences influence serum-modulated expression of a human dihydrofolate reductase minigene.
Breast Neoplasms
A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users.
Breast Neoplasms
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Breast Neoplasms
Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Breast Neoplasms
Chapter 4 molecular mechanisms of adaptation to folate deficiency.
Breast Neoplasms
CODING POLYPURINE HAIRPINS CAUSE TARGET-INDUCED CELL DEATH IN BREAST CANCER CELLS.
Breast Neoplasms
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Breast Neoplasms
Design, synthesis of methotrexate-diosgenin conjugates and biological evaluation of their effect on methotrexate transport-resistant cells.
Breast Neoplasms
Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2.
Breast Neoplasms
Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer.
Breast Neoplasms
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells.
Breast Neoplasms
Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line.
Breast Neoplasms
Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells.
Breast Neoplasms
Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Breast Neoplasms
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Breast Neoplasms
Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.
Breast Neoplasms
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).
Breast Neoplasms
Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Breast Neoplasms
Liposomal M-V-05: formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy.
Breast Neoplasms
Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.
Breast Neoplasms
Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells.
Breast Neoplasms
Pemetrexed: translational research in breast cancer.
Breast Neoplasms
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Breast Neoplasms
Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes.
Breast Neoplasms
Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum.
Breast Neoplasms
Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene.
Breast Neoplasms
Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition.
Breast Neoplasms
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Breast Neoplasms
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Breast Neoplasms
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Breast Neoplasms
Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells.
Breast Neoplasms
The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients.
Breast Neoplasms
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Breast Neoplasms
Translational research with pemetrexed in breast cancer.
Burkitt Lymphoma
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Carcinogenesis
A polycistronic transcript in transformed cells encodes the dihydrofolate reductase of herpesvirus saimiri.
Carcinogenesis
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in ?16HER2 transgenic mice.
Carcinogenesis
Restoration of gap-junctional intercellular communication in a communication-deficient rat liver cell mutant by transfection with connexin 43 cDNA.
Carcinogenesis
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Carcinoma
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
Carcinoma
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
Carcinoma
A second target of benzamide riboside: Dihydrofolate reductase.
Carcinoma
A Tribute to Bruce Chabner.
Carcinoma
Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug.
Carcinoma
Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Carcinoma
Characterization of the metabolism of perinecrotic cells in solid tumors by enzyme histochemistry.
Carcinoma
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Carcinoma
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Carcinoma
Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Carcinoma
Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]
Carcinoma
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Carcinoma
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Carcinoma
Expression of Thy-1 antigen on human melanoma cells.
Carcinoma
Histoenzymological study on desquamative cervico-vaginal cells.
Carcinoma
INTERACTION OF ORGANIC MERCURIAL COMPOUNDS WITH DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS.
Carcinoma
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Carcinoma
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Carcinoma
Procion dyes as affinity ligands and reporter groups for dihydrofolate reductase from Walker 256 carcinoma.
Carcinoma
PURIFICATION AND PROPERTIES OF DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS.
Carcinoma
Resistance mechanisms and their regulation in lung cancer.
Carcinoma
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Carcinoma
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Carcinoma
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Carcinoma
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Carcinoma
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Carcinoma
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Carcinoma
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Carcinoma, Ehrlich Tumor
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.
Carcinoma, Ehrlich Tumor
Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.
Carcinoma, Ehrlich Tumor
Role of the cellular oxidation-reduction state in methotrexate binding to dihydrofolate reductase and dissociation induced by reduced folates.
Carcinoma, Embryonal
Differential expression of the mouse and human Thy-1 gene in embryonal carcinoma cells.
Carcinoma, Embryonal
The Thy-1 glycoprotein is expressed in mouse embryonal carcinoma cells P19.
Carcinoma, Hepatocellular
A study of chromosomal changes associated with amplified dihydrofolate reductase genes in rat hepatoma cells and their dedifferentiated variants.
Carcinoma, Hepatocellular
Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Carcinoma, Hepatocellular
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Carcinoma, Hepatocellular
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Carcinoma, Hepatocellular
Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor.
Carcinoma, Hepatocellular
Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells.
Carcinoma, Hepatocellular
Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells.
Carcinoma, Hepatocellular
Heterologous antiserum to chemically induced rat non-T, non-B leukemia and its application to characterization of rat leukemias.
Carcinoma, Hepatocellular
Interaction between Gambogic acid and dihydrofolate reductase and synergistic lethal effects with methotrexate on hepatoma cells.
Carcinoma, Hepatocellular
Methotrexate analogues. 23. Synthesis, dihydrofolate reductase affinity, cytotoxicity, and in vivo antitumor activity of some putative degradation products of methotrexate-poly(L-lysine) conjugates.
Carcinoma, Hepatocellular
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Carcinoma, Hepatocellular
Purification and characterization of a major glycoprotein in rat hepatoma plasma membranes. One of the membrane proteins released by phosphatidylinositol-specific phospholipase C.
Carcinoma, Hepatocellular
Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Carcinoma, Hepatocellular
The characteristics and consequences of folate depletion in hepatoma cells in vitro by inhibition of dihydrofolate reductase.
Carcinoma, Hepatocellular
The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
Carcinoma, Hepatocellular
The properties of the secreted gamma-glutamyl hydrolases from H35 hepatoma cells.
Carcinoma, Hepatocellular
The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
Carcinoma, Hepatocellular
[Cytochemical study of cells of primary and disseminated ascite Yoshida tumor cells]
Carcinoma, Non-Small-Cell Lung
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Carcinoma, Non-Small-Cell Lung
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Carcinoma, Non-Small-Cell Lung
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Carcinoma, Non-Small-Cell Lung
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Carcinoma, Non-Small-Cell Lung
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Carcinoma, Non-Small-Cell Lung
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
Carcinoma, Ovarian Epithelial
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Carcinoma, Ovarian Epithelial
[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Carcinoma, Renal Cell
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Carcinoma, Squamous Cell
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
Carcinoma, Squamous Cell
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
Carcinoma, Squamous Cell
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Carcinoma, Squamous Cell
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Carcinoma, Squamous Cell
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Carcinoma, Squamous Cell
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Carcinoma, Squamous Cell
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Carcinoma, Squamous Cell
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Carcinosarcoma
Evaluation of 1-(3,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride effect on nucleic acid and protein syntheses using murine leukemia L-1210 cells.
Carcinosarcoma
Procion dyes as affinity ligands and reporter groups for dihydrofolate reductase from Walker 256 carcinoma.
Carcinosarcoma
Purification and characterization of dihydrofolate reductase from Walker 256 carcinosarcoma.
Carcinosarcoma
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
Cardiovascular Diseases
Dihydrofolate reductase and biopterin recycling in cardiovascular disease.
Cataract
The enzymatic activities of GTP cyclohydrolase, sepiapterin reductase, dihydropteridine reductase and dihydrofolate reductase; and tetrahydrobiopterin content in mammalian ocular tissues and in human senile cataracts.
Chagas Disease
Acute Trypanosoma cruzi infection differentially affects CD3 and Thy-1 mediated T cell activation.
Chagas Disease
Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen.
Chagas Disease
Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Chagas Disease
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Cholera
Control of Thy-1 glycoprotein expression in cultures of PC12 cells.
Cholera
Glycosylphosphatidyl inositol-anchored proteins and fyn kinase assemble in noncaveolar plasma membrane microdomains defined by reggie-1 and -2.
Cholera
Increased intracellular cyclic AMP differentially modulates nerve growth factor induction of three neuronal recognition molecules involved in neurite outgrowth.
Cholera
Independent mobility of cholera toxin binding sites and Thy-1 alloantigen on mouse thymocytes.
Cholera
Lipid domain structure of the plasma membrane revealed by patching of membrane components.
Cholera
Mechanism of catecholamine-mediated destabilization of messenger RNA encoding Thy-1 protein in T-lineage cells.
Cholera
The relationship between cholera toxin receptor and the Thy-1 antigen determinants.
Chondroma
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Chondrosarcoma
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Choriocarcinoma
Dihydrofolate reductase transcript level is not suitable for methotrexate-resistance prediction in choriocarcinoma cell line.
Choriocarcinoma
Methotrexate-induced resistance to dactinomycin in choriocarcinoma.
Choriocarcinoma
[Fundamental and clinical study of chemotherapy of refractory choriocarcinoma]
Choriocarcinoma
[Mechanisms of development of resistance to methotrexate in choriocarcinoma cells]
Choroidal Neovascularization
Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.
Choroidal Neovascularization
Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and Migration: Implications in Neovascular Age-Related Macular Degeneration.
Cleft Lip
Common polymorphism in the glycine N-methyltransferase gene as a novel risk factor for cleft lip with or without cleft palate.
Cleft Lip
Evidence of the involvement of the DHFR gene in nonsyndromic cleft lip with or without cleft palate.
Cleft Lip
The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role.
Cleft Palate
Common polymorphism in the glycine N-methyltransferase gene as a novel risk factor for cleft lip with or without cleft palate.
Cleft Palate
Evidence of the involvement of the DHFR gene in nonsyndromic cleft lip with or without cleft palate.
Cleft Palate
The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role.
Coinfection
High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations.
Coinfection
Plasmodium falciparum DHFR and DHPS Mutations Are Associated With HIV-1 Co-Infection and a Novel DHPS Mutation I504T Is Identified in Western Kenya.
Colitis
Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.
Colonic Neoplasms
Antitumor Therapy Based on Cellular Competition.
Colonic Neoplasms
Association of MTHFR, MTR, MTRR, RFC1, and DHFR Gene Polymorphisms with Susceptibility to Sporadic Colon Cancer.
Colonic Neoplasms
Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Colonic Neoplasms
Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA.
Colonic Neoplasms
Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells.
Colonic Neoplasms
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
Colonic Neoplasms
Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.
Colonic Neoplasms
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Colonic Neoplasms
Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells.
Colorectal Neoplasms
A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk.
Colorectal Neoplasms
Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
Colorectal Neoplasms
Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Colorectal Neoplasms
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats.
Colorectal Neoplasms
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Colorectal Neoplasms
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Colorectal Neoplasms
New agents for colon and breast cancer.
Colorectal Neoplasms
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Colorectal Neoplasms
Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-1 antibody-ricin conjugate.
Communicable Diseases
Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
Communicable Diseases
Antifolate agents: a patent review (2010 - 2013).
Communicable Diseases
Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges.
Communicable Diseases
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Communicable Diseases
Inhibitors of dihydrofolic acid reductase in the therapy of infectious diseases.
Communicable Diseases
Pharmacoinformatic Study on the Selective Inhibition of the Protozoan Dihydrofolate Reductase Enzymes.
Communicable Diseases
Repositioning of DHFR Inhibitors.
Communicable Diseases
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Community-Acquired Infections
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Confusion
Expression of the Thy-1 gene in human T lymphoid cell lines.
Congenital Abnormalities
Chemical teratogenesis in humans: biochemical and molecular mechanisms.
Congenital Abnormalities
Folic acid antagonist use before and during pregnancy and risk for selected birth defects.
Congenital Abnormalities
Methotrexate-resistant form of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate.
Crohn Disease
Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.
Cryptosporidiosis
Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.
Cryptosporidiosis
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum.
Cryptosporidiosis
Targeting DHFR in parasitic protozoa.
Cysts
Culture of tissue-cyst forming strain of Toxoplasma gondii and the effect of cyclic AMP and pyrimidine salvage inhibitors.
Cysts
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Cytomegalovirus Infections
Downregulation of the cellular adhesion molecule Thy-1 (CD90) by cytomegalovirus infection of human fibroblasts.
Cytomegalovirus Infections
E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection.
Cytomegalovirus Infections
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Dehydration
Plasticity of neurohypophysial terminals with increased hormonal release during dehydration: ultrastructural and biochemical analyses.
Demyelinating Diseases
A novel approach to 32-channel peripheral nervous system myelin imaging in vivo, with single axon resolution.
Demyelinating Diseases
Acute leukoencephalopathy due to pyrimethamine. An insight into methotrexate neurotoxicity?
Dermatitis
[The role of immunity on the development of dermatitis in NC mice]
Dermatitis, Contact
Changes in expression of Ia, Thy-1, and Ly-5 antigens in epidermal cells during delayed contact sensitivity reactions in mice: flow cytometric analysis.
Diabetes Mellitus, Type 1
High-resolution linkage mapping for susceptibility genes in human polygenic disease: insulin-dependent diabetes mellitus and chromosome 11q.
Diabetes Mellitus, Type 1
Non-HLA genetic factors and insulin dependent diabetes mellitus in the Japanese: TCRA, TCRB and TCRG, INS, THY1, CD3D and ETS1.
dihydrofolate reductase deficiency
Conditional dihydrofolate reductase deficiency due to transposon Tn5tac1 insertion downstream from the folA gene in Escherichia coli.
dihydrofolate reductase deficiency
Congenital errors of folate metabolism.
dihydrofolate reductase deficiency
Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement.
dihydrofolate reductase deficiency
Dihydrofolate reductase deficiency causing megaloblastic anemia in two families.
dihydrofolate reductase deficiency
Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.
dihydrofolate reductase deficiency
Dihydrofolate reductase mutations-associated megaloblastic anemia and cerebral folate deficiency.
dihydrofolate reductase deficiency
Expression and amplification of engineered mouse dihydrofolate reductase minigenes.
dihydrofolate reductase deficiency
Hereditary abnormal transcobalamin II previously diagnosed as congenital dihydrofolate reductase deficiency.
dihydrofolate reductase deficiency
Hereditary dihydrofolate reductase deficiency with megaloblastic anemia.
dihydrofolate reductase deficiency
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
dihydrofolate reductase deficiency
Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.
dihydrofolate reductase deficiency
Loss of Thy-1 inhibits alveolar development in the newborn mouse lung.
dihydrofolate reductase deficiency
Supplementation of serum free media with HT is not sufficient to restore growth properties of DHFR(-/-) cells in fed-batch processes - Implications for designing novel CHO-based expression platforms.
dihydrofolate reductase deficiency
Thy-1 (CD90) promotes bone formation and protects against obesity.
dihydrofolate reductase deficiency
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
dihydrofolate reductase deficiency
Update and new concepts in vitamin responsive disorders of folate transport and metabolism.
Diphtheria
Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin.
Diphtheria
Characterization of membrane translocation by anthrax protective antigen.
Diphtheria
Human dihydrofolate reductase gene is located in chromosome 5 and is unlinked to the related pseudogenes.
Distemper
Immunohistochemical analysis of the lymphoid organs of dogs naturally infected with canine distemper virus.
Down Syndrome
19-base pair deletion polymorphism of the dihydrofolate reductase (DHFR) gene: maternal risk of Down syndrome and folate metabolism.
Down Syndrome
DHFR 19-bp Deletion and SHMT C1420T Polymorphisms and Metabolite Concentrations of the Folate Pathway in Individuals with Down Syndrome.
Down Syndrome
Dihydrofolate Reductase (DHFR) del19bp Polymorphism and Down Syndrome Offspring.
Drug-Related Side Effects and Adverse Reactions
Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.
Dysentery, Bacillary
Phytochemical constituents of Inula britannica as potential inhibitors of dihydrofolate reductase: A strategic approach against shigellosis.
Elephantiasis, Filarial
Exploration of 2, 4-diaminopyrimidine and 2, 4-diamino-s-triazine derivatives as potential antifilarial agents.
Elephantiasis, Filarial
Targeting folate metabolism for therapeutic option: A bioinformatics approach.
Encephalomyelitis
Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice.
Encephalomyelitis, Autoimmune, Experimental
Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Encephalomyelitis, Autoimmune, Experimental
Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice.
Escherichia coli Infections
Peritoneal gamma delta T cells induced by Escherichia coli infection in mice. Correlation between Thy-1 phenotype and host minor lymphocyte-stimulating phenotype.
Fanconi Anemia
Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines.
Fanconi Anemia
Repair of 8-methoxypsoralen + UVA-induced damage in specific sequences in chromosomal and episomal DNA in human cells.
Fasciculation
Morphology and growth of embryonic, human dorsal root ganglion explants in long-term culture: expression of cell type-specific markers during early differentiation.
Fetal Diseases
Methotrexate-resistant form of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate.
Fibrosarcoma
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid.
Fibrosarcoma
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
Fibrosarcoma
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
Fibrosarcoma
Satellite DNA sequences flank amplified DHFR domains in marker chromosomes of mouse fibrosarcoma cells.
Fibrosarcoma
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Filariasis
Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti.
Filariasis
In vitro biological evaluation of biguanides and dihydrotriazines against Brugia malayi and folate reversal studies.
Gastrointestinal Stromal Tumors
Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors.
Gaucher Disease
In vivo methotrexate selection of murine hemopoietic cells transduced with a retroviral vector for Gaucher disease.
Glioma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Glioma
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Glioma
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
Glioma
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Glioma
Dihydrofolate reductase activity in primary brain tumors in children.
Glioma
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Glioma
Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.
Glioma
Genomic changes in progression of low-grade gliomas.
Glioma
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Glomerulonephritis
A specific Thy-1 molecular epitope expressed on rat mesangial cells.
Glomerulonephritis
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Glomerulonephritis
C5a Induces the Synthesis of IL-6 and TNF-? in Rat Glomerular Mesangial Cells through MAPK Signaling Pathways.
Glomerulonephritis
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Glomerulonephritis
Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis.
Glomerulonephritis
Induction of renal cell apoptosis by antibodies and complement.
Glomerulonephritis
Inhibition of Inducible Nitric Oxide Synthase Alters Thy-1 Glomeruonephritis in Rats.
Glomerulonephritis
KLF6 Acetylation Promotes Sublytic C5b-9-Induced Production of MCP-1 and RANTES in Experimental Mesangial Proliferative Glomerulonephritis.
Glomerulonephritis
Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-1 nephritis.
Glomerulonephritis
Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis.
Glomerulonephritis
Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat.
Glomerulonephritis
Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats.
Glomerulonephritis
Selective expression of TGF-beta2 and TGF-beta3 isoforms in early mesangioproliferative glomerulonephritis.
Glomerulonephritis
Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.
Glomerulonephritis
Sublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation.
Glomerulonephritis
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis through the Cascade Pathway of MEKK2-p38 MAPK-IRF-1-TRADD-Caspase 8 in Rat Thy-1 Nephritis.
Glomerulonephritis
Sublytic C5b-9 induces glomerular mesangial cell proliferation via ERK1/2-dependent SOX9 phosphorylation and acetylation by enhancing Cyclin D1 in rat Thy-1 nephritis.
Glomerulonephritis
Sublytic C5b-9 Induces IL-23 and IL-36a Production by Glomerular Mesangial Cells via PCAF-Mediated KLF4 Acetylation in Rat Thy-1 Nephritis.
Glomerulonephritis
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation.
Glomerulonephritis
Sublytic C5b-9 triggers glomerular mesangial cell proliferation via enhancing FGF1 and PDGF? gene transcription mediated by GCN5-dependent SOX9 acetylation in rat Thy-1 nephritis.
Glomerulonephritis
The characterization of a specific Thy-1 molecular epitope expressed on rat mesangial cells.
Glomerulonephritis
The complement C5b-9 complexes induced injury of glomerular mesangial cells in rats with Thy-1 nephritis by increasing nitric oxide synthesis.
Glomerulonephritis
Transient expression of type I collagen in glomeruli with anti-Thy-1 antibody-induced mesangial proliferative lesions.
Glomerulonephritis
TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.
Glomerulonephritis
[VEGF is an essential molecule for glomerular endothelial cells and its excretion in urine might be a unique marker of glomerular injury]
Glomerulonephritis, Membranoproliferative
Gene expression profile and overexpression of apoptosis-related genes (NGFI-B and Gadd 45 gamma) in early phase of Thy-1 nephritis model.
Graft vs Host Disease
Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies.
Graft vs Host Disease
Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
Graft vs Host Disease
Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.
Graves Ophthalmopathy
Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1.
Head and Neck Neoplasms
A second target of benzamide riboside: Dihydrofolate reductase.
Head and Neck Neoplasms
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
Head and Neck Neoplasms
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Healthcare-Associated Pneumonia
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.
Hematologic Neoplasms
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics.
Hepatitis
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Hepatitis B
A recombinant Chinese hamster ovary cell line containing a 300-fold amplified tetramer of the hepatitis B genome together with a double selection marker expresses high levels of viral protein.
Hepatitis B
Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA.
Hepatitis B
Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure.
Hepatitis B
Key determinants in the occurrence of clonal variation in humanized antibody expression of cho cells during dihydrofolate reductase mediated gene amplification.
Hepatitis B
Murine cells carrying integrated tandem genomes of hepatitis B virus DNA transcribe RNAs from endogenous promoters on both viral strands and express middle and major viral envelope proteins.
Hepatitis B
Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin.
Hepatitis B
Ultrastructural studies of fibroblasts transfected with hepatitis B virus DNA.
Hepatitis B
[Application of dhfr gene negative Chinese hamster ovary cell line to express hepatitis B virus surface antigen]
Hepatitis C
Substrate requirements of hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Escherichia coli.
Hernias, Diaphragmatic, Congenital
Disruption of THY-1 signaling in alveolar lipofibroblasts in experimentally induced congenital diaphragmatic hernia.
Herpes Simplex
A gene for dihydrofolate reductase in a herpesvirus.
Herpes Simplex
Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene.
Herpes Simplex
Expression and regulation of glycoprotein C gene of herpes simplex virus 1 resident in a clonal L-cell line.
Herpes Simplex
Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Herpes Simplex
Insertion of new genes into bone marrow cells of mice.
Herpes Simplex
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
Herpes Simplex
Second gene expression in bicistronic constructs using short synthetic intercistrons and viral IRES sequences.
Herpes Simplex
Synthesis of dihydrofolate reductase and metabolism of related RNA in a methotrexate resistant human cell line infected with herpes simplex virus type 2.
Herpes Simplex
Thy-1 tk transgenic mice with a conditional lymphocyte deficiency.
Herpes Simplex
Towards the application of Tc toxins as a universal protein translocation system.
Herpes Simplex
Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro.
Hirschsprung Disease
Impaired expression of neural cell adhesion molecule L1 in the extrinsic nerve fibers in Hirschsprung's disease.
Histiocytic Sarcoma
Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping.
HIV Infections
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Hodgkin Disease
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Huntington Disease
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.
Hyperlipidemias
Oxidant stress in hyperlipidemia-induced renal damage.
Hypersensitivity
Conditional dihydrofolate reductase deficiency due to transposon Tn5tac1 insertion downstream from the folA gene in Escherichia coli.
Hypersensitivity
Differential sensitivity to acute cholesterol lowering of activation mediated via the high-affinity IgE receptor and Thy-1 glycoprotein.
Hypersensitivity
Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Hypersensitivity
Functional heterogeneity of Thy-1 membrane microdomains in rat basophilic leukemia cells.
Hypersensitivity
Genetic control of contract hypersensitivity. II. Suppressor cells induced by intravenous injection of DNP-coupled syngeneic spleen cells possessing thy-1 antigen, I-J determinant, Lyt-2+, 3+ antigen, FcR- and DNP-membrane binding receptor on their surfaces.
Hypersensitivity
Hypersensitivity to low level cytotoxic stress in mouse cells with high levels of DHFR gene amplification.
Hypersensitivity
Nucleotide sequence and nuclease hypersensitivity of the Chinese hamster dihydrofolate reductase gene promoter region.
Hypersensitivity
Only the promoter region of the constitutively expressed normal and amplified human dihydrofolate reductase gene is DNase I hypersensitive and undermethylated.
Hypersensitivity
Presence of negative torsional tension in the promoter region of the transcriptionally poised dihydrofolate reductase gene in vivo.
Hypersensitivity
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Hypertension
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Hypertension
Endothelium-specific sepiapterin reductase deficiency in DOCA-salt hypertension.
Hypertension
Glomerular damage in experimental proliferative glomerulonephritis under glomerular capillary hypertension.
Hypertension
Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese.
Hypertension
Knockout of dihydrofolate reductase in mice induces hypertension and abdominal aortic aneurysm via mitochondrial dysfunction.
Hypertension
Novel Treatment of Hypertension by Specifically Targeting E2F for Restoration of Endothelial Dihydrofolate Reductase and eNOS Function Under Oxidative Stress.
Hypertension
Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications.
Hypertension
Significant association between DHFR promoter methylation and ischemic stroke in a Chinese hypertensive population.
Hypertension
Tubulointerstitial injury of Thy-1 nephritis in uninephrectomized stroke-prone spontaneously hypertensive rats.
Hypertension, Renovascular
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Ichthyosis
In vitro colonization of thymic primordia by adult bone marrow cells: light scatter profile and separation by flow cytometry.
Idiopathic Pulmonary Fibrosis
Absence of Thy-1 results in TGF-? induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts.
Idiopathic Pulmonary Fibrosis
Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction.
Idiopathic Pulmonary Fibrosis
Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts.
Idiopathic Pulmonary Fibrosis
Hypoxia-induced dna hypermethylation in human pulmonary fibroblasts is ssociated with thy-1 promoter methylation and the development of a pro-fibrotic Phenotype.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri.
Idiopathic Pulmonary Fibrosis
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.
Idiopathic Pulmonary Fibrosis
Thy-1 attenuates TNF-alpha-activated gene expression in mouse embryonic fibroblasts via Src family kinase.
Immune System Diseases
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Immune System Diseases
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Infarction, Middle Cerebral Artery
Local hemodynamics dictate long-term dendritic plasticity in peri-infarct cortex.
Infections
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
Infections
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.
Infections
A new reporter system for detection of retroviral infection.
Infections
Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.
Infections
Acute Trypanosoma cruzi infection differentially affects CD3 and Thy-1 mediated T cell activation.
Infections
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.
Infections
Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model.
Infections
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
Infections
Antiparasitic effect of in-feed inhibitors of folic acid synthesis and dihydrofolate reductase against ciliate Cryptocaryon irritans infection in the red sea bream Pagrus major and against ciliate Ichthyophthirius multifiliis infection in black pop-eyed goldfish Carassius auratus
Infections
Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response.
Infections
Bacteriophage T4-coded dihydrofolate reductase: synthesis, turnover, and location of the virion protein.
Infections
Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?
Infections
CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein.
Infections
Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-like Process.
Infections
Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand.
Infections
Characterization of trimethoprim resistant E. coli dihydrofolate reductase mutants by mass spectrometry and inhibition by propargyl-linked antifolates.
Infections
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Infections
Comparative activity and properties of lactate dehydrogenase, xanthine dehydrogenase, and dihydrofolate reductase in normal and Brugia pagangi-infected Aedes aegypti.
Infections
Comparison of two nested PCR methods for the detection of human malaria.
Infections
Computational analysis of binding between malarial dihydrofolate reductases and anti-folates.
Infections
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Infections
Contribution of Thy-1-CD4+ T cells to the disorganization of lymphoid follicles in retrovirus-induced immunodeficiency syndrome, MAIDS.
Infections
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Infections
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction.
Infections
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Infections
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
Infections
Dihydrofolate reductase as a target for chemotherapy in parasites.
Infections
Dihydrofolate Reductase Is a Valid Target for Antifungal Development in the Human Pathogen Candida albicans.
Infections
Discovery of traditional Chinese medicine derived compounds as wild type and mutant Plasmodium falciparum dihydrofolate reductase inhibitors: Induced fit docking and ADME studies.
Infections
Downregulation of the cellular adhesion molecule Thy-1 (CD90) by cytomegalovirus infection of human fibroblasts.
Infections
Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant.
Infections
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Infections
Epidemiology of malaria in the forest-savannah transitional zone of Ghana.
Infections
Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia.
Infections
Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in nanoro, burkina faso.
Infections
Evidence that sulfisoxazole, an antibacterial sulfonamide, can adversely affect the development of Brugia pahangi in Aedes aegypti mosquitoes.
Infections
Expression of dihydrofolate reductase, and of the adjacent EIb region, in an Ad5-dihydrofolate reductase recombinant virus.
Infections
First Three-Dimensional Structure of Toxoplasma gondii Thymidylate Synthase-Dihydrofolate Reductase: Insights for Catalysis, Interdomain Interactions, and Substrate Channeling.
Infections
Function of T4D structural dihydrofolate reductase in bacteriophage infection.
Infections
Functions of baseplate components in bacteriophage T4 infection. I. Dihydrofolate reductase and dihydropteroylhexaglutamate.
Infections
Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar.
Infections
Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia.
Infections
High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan.
Infections
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Infections
High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Infections
Historical trends and new surveillance of Plasmodium falciparum drug resistance markers in Angola.
Infections
Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells.
Infections
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Infections
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Infections
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Infections
Inhibition of Stenotrophomonas maltophilia dihydrofolate reductase by methotrexate: a single slow-binding process.
Infections
Investigational antimicrobial drugs for bloodstream infections.
Infections
Isolation of specific antigen-reactive T-cell clones from nude (nu/nu) mice infected with Mesocestoides corti.
Infections
Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Infections
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Infections
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali.
Infections
Low prevalence of dihydro folate reductase (dhfr) and dihydropteroate synthase (dhps) quadruple and quintuple mutant alleles associated with SP resistance in Plasmodium vivax isolates of West Bengal, India.
Infections
Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan.
Infections
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Infections
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.
Infections
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
Infections
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
Infections
Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.
Infections
Murine cytomegalovirus induces expression and enzyme activity of cellular dihydrofolate reductase in quiescent cells.
Infections
Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment.
Infections
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil.
Infections
Novel gene-sequence markers for isolate tracking within Monilinia fructicola lesions.
Infections
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Infections
Peritoneal gamma delta T cells induced by Escherichia coli infection in mice. Correlation between Thy-1 phenotype and host minor lymphocyte-stimulating phenotype.
Infections
Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
Infections
Plasmodium falciparum infection dynamics and transmission potential following treatment with sulfadoxine-pyrimethamine.
Infections
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Infections
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis.
Infections
Polyoma virus and cyclic AMP-mediated control of dihydrofolate reductase mRNA abundance in methotrexate-resistant mouse fibroblasts.
Infections
Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.
Infections
Posttranscriptional control of DHFR gene expression during adenovirus 2 infection.
Infections
Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
Infections
Presence of novel triple mutations in the pvdhfr from Plasmodium vivax in Mangaluru city area in the southwestern coastal region of India.
Infections
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Infections
Productive murine leukemia virus (MuLV) infection of EL4 T-lymphoblastoid cells: selective elevation of H-2 surface expression and possible association of Thy-1 antigen with viruses.
Infections
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
Infections
QSAR analysis of 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4-diaminopyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Infections
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis.
Infections
Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
Infections
Role of adenovirus type 2 early region 4 in the early-to-late switch during productive infection.
Infections
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes.
Infections
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation.
Infections
Stages in development of mink cell focus-inducing (MCF) virus-accelerated leukemia in AKR mice.
Infections
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Infections
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution.
Infections
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Infections
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Infections
Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy.
Infections
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Infections
Synthesis of dihydrofolate reductase and metabolism of related RNA in a methotrexate resistant human cell line infected with herpes simplex virus type 2.
Infections
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Infections
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
Infections
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
Infections
The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.
Infections
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
Infections
The effect of polyoma virus, serum factors, and dibutyryl cyclic AMP on dihydrofolate reductase synthesis, and the entry of quiescent cells into S phase.
Infections
The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
Infections
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
Infections
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Infections
Travel and the emergence of high-level drug resistance in Plasmodium falciparum in southwest Uganda: results from a population-based study.
Infections
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
Infections
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Infections
Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase-dihydrofolate reductase.
Influenza, Human
Comparative behavior of membrane protein-antibody complexes on motile fibroblasts: implications for a mechanism of capping.
Influenza, Human
Functional expression of influenza A viral nucleoprotein in cells transformed with cloned DNA.
Influenza, Human
Glycosylation: heterogeneity and the 3D structure of proteins.
Influenza, Human
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
Influenza, Human
Lipid domain structure of the plasma membrane revealed by patching of membrane components.
Influenza, Human
Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
Intellectual Disability
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food.
Intracranial Aneurysm
Polymorphisms of homocysteine metabolism are associated with intracranial aneurysms.
Iron Deficiencies
Effects of chronic alcohol consumption and iron deficiency on maternal folate status and reproductive outcome in mice.
Ischemic Stroke
Significant association between DHFR promoter methylation and ischemic stroke in a Chinese hypertensive population.
Isosporiasis
Refractory isosporiasis.
Kidney Neoplasms
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Kidney Neoplasms
Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities.
Laryngeal Neoplasms
Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
Leiomyosarcoma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Leishmaniasis
Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase.
Leishmaniasis
Homology modelling of the dihydrofolate reductase-thymidylate synthase bifunctional enzyme of Leishmania major, a potential target for rational drug design in leishmaniasis.
Leishmaniasis
Identification of Selective Inhibitors of LdDHFR Enzyme Using Pharmacoinformatic Methods.
Leishmaniasis
Identification of selective LdDHFR inhibitors using quantum chemical and molecular modeling approach.
Leishmaniasis
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Leishmaniasis
Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.
Leishmaniasis
Structure based designing of benzimidazole/benzoxazole derivatives as anti-leishmanial agents.
Leishmaniasis
Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
Leishmaniasis, Cutaneous
Effect of dihydrofolate reductase inhibitors on experimental cutaneous leishmaniasis, with especial emphasis on Leishmania isolates from Latin-America.
Leishmaniasis, Visceral
Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies.
Leukemia
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
Leukemia
A comparison of the inhibition of bovine and murine leukemia dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-X-phenyl)-s-triazines.
Leukemia
A direct ligand-binding radioassay for the measurement of methotrexate in tissues and biological fluids.
Leukemia
A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.
Leukemia
A histochemical study on the dihydrofolate reductase activity in leukemia.
Leukemia
A new myeloblastic leukemia cell line with double minute chromosomes. Induction of methotrexate resistance and dihydrofolate reductase gene amplification.
Leukemia
A nonfunctional protein in human leukemia cells reacts with antiserum to dihydrofolate reductase from L1210 leukemia cells.
Leukemia
A second target of benzamide riboside: Dihydrofolate reductase.
Leukemia
A unified framework for using neural networks to build QSARs.
Leukemia
Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Leukemia
Age-related changes in cell surface antigens of preleukemic AKR thymocytes.
Leukemia
Aggregation of Thy-1 glycoprotein induces tyrosine phosphorylation of different proteins in isolated rat mast cells and rat basophilic leukemia cells.
Leukemia
AKR murine thymic leukemias are from a distinct thymic cell lineage and do not express the beta chain of the T-cell antigen receptor.
Leukemia
Analogues of methotrexate.
Leukemia
Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells.
Leukemia
Atypical transient state kinetics of recombinant human dihydrofolate reductase produced by hysteretic behavior. Comparison with dihydrofolate reductases from other sources.
Leukemia
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Leukemia
Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Leukemia
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Leukemia
Chemistry and antitumor evaluation of selected classical 2,4-diaminoquinazoline analogues of folic acid.
Leukemia
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
Leukemia
Comparison of quantitative structure-activity relationships of the inhibition of leukemia cells in culture with the inhibition of dihydrofolate reductase from leukemia cells and other cell types.
Leukemia
Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
Leukemia
Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance.
Leukemia
Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate.
Leukemia
Decrease in Thy-1 expression on peripheral CD34 positive cells induced by G-CSF mobilization. The Tohoku Children Leukemia Study Group.
Leukemia
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction.
Leukemia
Development of an amphotropic, high-titer retrovirus vector expressing the dihydrofolate reductase gene and conferring methotrexate resistance.
Leukemia
Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells.
Leukemia
DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair.
Leukemia
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
Leukemia
Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Leukemia
Differential sensitivity to acute cholesterol lowering of activation mediated via the high-affinity IgE receptor and Thy-1 glycoprotein.
Leukemia
Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells.
Leukemia
Dihydrofolate reductase gene expression characterized by the PCR assay in human leukemia cells.
Leukemia
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Leukemia
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Leukemia
Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
Leukemia
Engagement of Phospholipid Scramblase 1 in Activated Cells: IMPLICATION FOR PHOSPHATIDYLSERINE EXTERNALIZATION AND EXOCYTOSIS.
Leukemia
Enhanced therapeutic effect of methotrexate in experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide.
Leukemia
Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies.
Leukemia
Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line.
Leukemia
Evidence for kinetic and immunologic heterogeneity of dihydrofolate reductase in L1210 leukemia cells.
Leukemia
Evidence for two molecular species of dihydrofolate reductase in amethopterin resistant and sensitive cells of the mouse leukemia L4946.
Leukemia
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Leukemia
Exogenous administration of gangliosides inhibits Fc epsilon RI-mediated mast cell degranulation by decreasing the activity of phospholipase C gamma.
Leukemia
Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines.
Leukemia
Expression of human alpha 1 antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer.
Leukemia
Expression of Thy-1 antigen (CDw90) on adult acute leukemia blast cells.
Leukemia
Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Leukemia
Flow cytometric analysis of Thy-1 expression in CD34-positive acute leukemia.
Leukemia
Folate analogues altered in the C9-N10 bridge region. 18. Synthesis and antitumor evaluation of 11-oxahomoaminopterin and related compounds.
Leukemia
Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Leukemia
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Leukemia
Functional expression of the endogenous Thy-1 gene and the transfected murine Thy-1.2 gene in rat basophilic leukemia cells.
Leukemia
Functional heterogeneity of Thy-1 membrane microdomains in rat basophilic leukemia cells.
Leukemia
Further studies on substituted quinazolines and triazines as inhibitors of a methotrexate-insensitive murine dihydrofolate reductase.
Leukemia
Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity.
Leukemia
Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.
Leukemia
Gene amplification in a leukemic patient treated with methotrexate.
Leukemia
Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.
Leukemia
Growth properties and alloantigenic expression of murine lymphoblastoid cell lines.
Leukemia
High-throughput drug screening identifies pyrimethamine as a potent and selective inhibitor of acute myeloid leukemia.
Leukemia
Human leukemia and normal leukocytes contain a species of immunoreactive but nonfunctional dihydrofolate reductase.
Leukemia
Identification of a high-molecular-weight nonfunctional protein in L1210 leukemia cells with common antigenic determinants to dihydrofolate reductase.
Leukemia
Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.
Leukemia
Immunofluorescence and histologic studies of virus-induced murine lymphocytic leukemias.
Leukemia
Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.
Leukemia
Improved purification of tetrahydrofolate dehydrogenase from L1210 leukemia by affinity chromatography.
Leukemia
Inhibition of a methotrexate-insensitive dihydrofolate reductase from L5178Y cells by substituted triazines and quinazolines.
Leukemia
Inhibition of dihydrofolate reductase, methotrexate transport, and growth of methotrexate-sensitive and -resistant L1210 leukemia cells in vitro by 5-substituted 2,4-diaminoquinazolines.
Leukemia
Inhibition of thymidylate synthetase and dihydrofolate reductase by naturally occurring oligoglutamate derivatives of folic acid.
Leukemia
Interaction of D, L-erythro- and D,L-threo-gamma-fluoromethotrexate with human leukemia cell dihydrofolate reductase.
Leukemia
Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
Leukemia
Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-benzamidomethyl) phenoxymethyl]pyrimidine. II.
Leukemia
Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. II.
Leukemia
Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. I.
Leukemia
Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.
Leukemia
Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
Leukemia
Irreversible enzyme inhibitors. CXXXIV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
Leukemia
Irreversible enzyme inhibitors. CXXXV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(p-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
Leukemia
L1210 dihydrofolate reductase. Kinetics and mechanism of activation by various agents.
Leukemia
L1210 dihydrofolate reductase: activation and enhancement of methotrexate sensitivity.
Leukemia
Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.
Leukemia
Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
Leukemia
Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase.
Leukemia
Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase.
Leukemia
Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
Leukemia
Methotrexate analogues--XVII. Antitumor activity of 4-amino-4-deoxy-N10-methylpteroyl-D,L-homocysteic acid and its dual inhibition of dihydrofolate reductase and folyl polyglutamate synthetase.
Leukemia
Methotrexate analogues. 16. Importance of the side-chain amide carbonyl group as a structural determinant of biological activity.
Leukemia
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Leukemia
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Leukemia
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
Leukemia
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
Leukemia
Methotrexate analogues. 32. Chain extension, alpha-carboxyl deletion, and gamma-carboxyl replacement by sulfonate and phosphonate: effect on enzyme binding and cell-growth inhibition.
Leukemia
Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
Leukemia
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
Leukemia
Methotrexate-resistant human promyelocytic leukemia (HL-60) cells express a dihydrofolate reductase with altered properties associated with increased enzyme activity.
Leukemia
Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine.
Leukemia
Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.
Leukemia
Molecular basis of antifolate resistance.
Leukemia
Multiple forms of L1210 dihydrofolate reductase differing in affinity for methotrexate.
Leukemia
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Leukemia
Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.
Leukemia
Overproduction of two antigenically distinct forms of dihydrofolate reductase in a highly methotrexate-resistant mouse leukemia cell line.
Leukemia
Polyglutamyl and polylysyl derivatives of the lysine analogues of folic acid and homofolic acid.
Leukemia
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Leukemia
Polymorphism of dihydrofolate reductase from a methotrexate-resistant subline of L1210 cells.
Leukemia
Potential anticancer agents. XXIII. 1. Qualitative structure--activity relationship in the "classical" antifolates area.
Leukemia
Production, purification and characterization of biologically active recombinant human nerve growth factor.
Leukemia
Productive murine leukemia virus (MuLV) infection of EL4 T-lymphoblastoid cells: selective elevation of H-2 surface expression and possible association of Thy-1 antigen with viruses.
Leukemia
Protein tyrosine kinase Syk is involved in Thy-1 signaling in rat basophilic leukemia cells.
Leukemia
Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume.
Leukemia
Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells.
Leukemia
R plasmid dihydrofolate reductase with a dimeric subunit structure.
Leukemia
Rat lymphoid leukemia of T cell type induced by 7,12-dimethylbenz(alpha)anthracene. Immunological and enzymological characterization.
Leukemia
Rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after cessation of dihydrofolate reductase activity in stationary versus log phase L1210 leukemia cells.
Leukemia
Regiospecific gamma-conjugation of methotrexate to poly(L-lysine). Chemical and biological studies.
Leukemia
Regulation of Thy-1 gene expression by the methylation of the 5' region of Thy-1 gene and intracellular regulatory factors in immature B cells.
Leukemia
Resistance to methotrexate due to gene amplification in a patient with acute leukemia.
Leukemia
Somatic hybrid of thymus leukemia (.
Leukemia
Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells.
Leukemia
Synthesis and antifolate properties of 5,10-methylenetetrahydro-8,10-dideazaminopterin.
Leukemia
Synthesis and biological activity of folic acid and methotrexate analogues containing L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid.
Leukemia
Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.
Leukemia
Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate.
Leukemia
Synthesis of N-10-methyl-4-thiofolic acid and related compounds.
Leukemia
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Leukemia
The association of increased dihydrofolate reductase with amethopterin resistance in mouse leukemia.
Leukemia
The cytotoxic activity of 1-acyl- and 1,2-diacyl-4,4-diethyl-3,5-pyrazolidinediones.
Leukemia
The cytotoxicity and mode of action of 2,3,4-trisubstituted pyrroles and related derivatives in human Tmolt4 leukemia cells.
Leukemia
Thy-1 expression on blast cells from adult patients with acute myeloid leukemia.
Leukemia
Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
Leukemia
Thy-1-mediated activation of rat basophilic leukemia cells does not require co-expression of the high-affinity IgE receptor.
Leukemia
Thy-1-mediated activation of rat mast cells: the role of Thy-1 membrane microdomains.
Leukemia
Topography of plasma membrane microdomains and its consequences for mast cell signaling.
Leukemia
Transfer of a mutant dihydrofolate reductase gene into pre- and postimplantation mouse embryos by a replication-competent retrovirus vector.
Leukemia
Transitory expression of Thy-1 antigen in immature B cell lines.
Leukemia
Tricyclic 2,4-diaminopyrimidines with broad antifolate activity and the ability to inhibit Pneumocystis carinii growth in cultured human lung fibroblasts in the presence of leucovorin.
Leukemia
Trimethoprim interference in methotrexate assay by an enzyme inhibition assay kit.
Leukemia
[Acute mixed-cell human leukemia]
Leukemia
[CDw90 (Thy-1) expression on CD34 positive cells in peripheral blood stem cell harvest]
Leukemia
[Comparison of inhibitory effects of triazines on dihydrofolate reductase isolated from murine leukemia cells with the inhibition of growth of cells in culture]
Leukemia
[Cynomorium songaricum improves sperm count and motility and serum testosterone level and promotes proliferation of undifferentiated spermatogonia in oligoasthenospermia rats].
Leukemia
[Cytochemical study of tetrahydrofolate dehydrogenase in blast cells in acute leukemia]
Leukemia
[Detection of alterations of dihydrofolate reductase gene in folate-resistant leukemia cells by in vitro enzymatic amplification]
Leukemia
[Determination, properties and significance of dihydrofolic acid reductase in the white blood cells in leukemia.]
Leukemia L1210
Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay.
Leukemia L1210
ASSOCIATION OF INCREASED DIHYDROFOLATE REDUCTASE LEVELS AND CHROMOSOME ALTERATION IN AMETHOPTERIN-RESISTANT SUBLINES OF LEUKEMIA L1210.
Leukemia L1210
CYTOGENETICS OF MOUSE LEUKEMIA L1210. I. ASSOCIATION OF A SPECIFIC CHROMOSOME WITH DIHYDROFOLATE REDUCTASE ACTIVITY IN AMETHOPTERIN-TREATED SUBLINES.
Leukemia L1210
Dihydrofolate reductase activity and loss of resistance in an antifolate-resistant subline of leukemia L1210 after discontinuation of treatment.
Leukemia L1210
Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance.
Leukemia L1210
SELECTION OF CHROMOSOMAL VARIANT IN AMETHOPTERIN-RESISTANT SUBLINES OF LEUKEMIA L1210 WITH INCREASED LEVELS OF DIHYDROFOLATE REDUCTASE.
Leukemia, Erythroblastic, Acute
c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Cell surface molecules of Friend erythroleukemias: decrease in T200 glycoprotein expression after induction.
Leukemia, Erythroblastic, Acute
Evidence for an accessory component that increases the affinity of the erythropoietin receptor.
Leukemia, Erythroblastic, Acute
Murine erythroleukemia cell variants: isolation of cells that have amplified the dihydrofolate reductase gene and retained the ability to be induced to differentiate.
Leukemia, Erythroblastic, Acute
Regulated expression of amplified human beta globin genes.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytochemical study of tetrahydrofolate dehydrogenase in chronic lymphocytic leukemia cells.
Leukemia, Lymphoid
Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.
Leukemia, Lymphoid
Cytotoxicity of rhenium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor cells.
Leukemia, Lymphoid
The cytotoxicity of copper(II) complexes of heterocyclic thiosemicarbazones and 2-substituted pyridine N-oxides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytoenzymological-cytogenetical correlations concerning chronic granulocytic leukemia leucocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human leukemia and normal leukocytes contain a species of immunoreactive but nonfunctional dihydrofolate reductase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia]
Leukemia, Myeloid
Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Leukemia, Myeloid
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
Leukemia, Myeloid
Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies.
Leukemia, Myeloid
Thy-1 epitopes are expressed on murine myeloid leukemia and reticulum sarcoma cells.
Leukemia, Myeloid, Acute
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
Leukemia, Myeloid, Acute
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Leukemia, Myeloid, Acute
Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients.
Leukemia, Myeloid, Acute
Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.
Leukemia, Myeloid, Acute
Thy-1 expression on blast cells from adult patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
[CDw90 (Thy-1) expression on CD34 positive cells in peripheral blood stem cell harvest]
Leukemia, T-Cell
Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Leukemia, T-Cell
Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN.
Liver Cirrhosis
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.
Liver Cirrhosis
Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration.
Liver Diseases
Hepatic progenitor cells from adult human livers for cell transplantation.
Liver Failure, Acute
Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration.
Liver Neoplasms
The RFC1 80G>A, among Common One-Carbon Polymorphisms, Relates to Survival Rate According to DNA Global Methylation in Primary Liver Cancers.
Liver Neoplasms
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Liver Neoplasms
Wnt/?-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1.
Lung Injury
?v?3 Integrin drives fibroblast contraction and strain stiffening of soft provisional matrix during progressive fibrosis.
Lung Injury
Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury.
Lung Injury
Thy-1 interaction with Fas in lipid rafts regulates fibroblast apoptosis and lung injury resolution.
Lung Neoplasms
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Lung Neoplasms
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Lung Neoplasms
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Lung Neoplasms
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Lung Neoplasms
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Lung Neoplasms
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Lung Neoplasms
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Lung Neoplasms
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
Lung Neoplasms
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Lung Neoplasms
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
Lupus Nephritis
Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.
Lymphadenopathy
Characterization of lymphoproliferation induced by interactions between lprcg and gld genes.
Lymphocytic Choriomeningitis
Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation.
Lymphoma
5,10-Methylenetetrahydro-5-deazafolic acid and analogues: synthesis and biological activities.
Lymphoma
A mutant lymphoma cell line with a defective Thy-1 glycoprotein gene.
Lymphoma
A Thy-1 negative lymphoma cell variant defective in the formation of glycosyl-phosphatidylinositol membrane protein anchors.
Lymphoma
A Thy-1- mutant defining a gene acting in trans position to regulate cell-surface Thy-1 glycoprotein expression and Thy-1 messenger RNA content.
Lymphoma
Absence of Thy-1 antigen in L-cell X mouse lymphoma hybrids.
Lymphoma
Alterations in expression and glycosylation pattern of the Thy-1 glycoprotein during maturation and transformation of mouse T lymphocytes.
Lymphoma
Analysis of thy-1 variants of murine lymphoma cells.
Lymphoma
Anchoring of membrane proteins via phosphatidylinositol is deficient in two classes of Thy-1 negative mutant lymphoma cells.
Lymphoma
Anti-thymocyte autoimmunity in BALB/C mice accompanying immunization to a syngeneic lymphoma.
Lymphoma
Antibody to dihydrofolate reductase from a methotrexate-resistant subline of the L1210 lymphoma.
Lymphoma
Atypical mannolipids characterize Thy-1-negative lymphoma mutants.
Lymphoma
Biochemical analysis of glycophospholipids from wild-type mouse lymphoma cells and from Thy-1 negative mutants which do not add glycolipid-anchored proteins.
Lymphoma
Characterization of glycophospholipid intermediate in the biosynthesis of glycophosphatidylinositol anchors accumulating in the Thy-1-negative lymphoma line SIA-b.
Lymphoma
Characterization of putative glycoinositol phospholipid anchor precursors in mammalian cells. Localization of phosphoethanolamine.
Lymphoma
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase.
Lymphoma
Class E Thy-1 negative mouse lymphoma cells utilize an alternate pathway of oligosaccharide processing to synthesize complex-type oligosaccharides.
Lymphoma
Class F Thy-1-negative murine lymphoma cells are deficient in ether lipid biosynthesis.
Lymphoma
Clinical resistance to antimetabolites.
Lymphoma
Defective glycosyl phosphatidylinositol biosynthesis in extracts of three Thy-1 negative lymphoma cell mutants.
Lymphoma
Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones.
Lymphoma
Detection of a Thy-1 precursor in human T lymphoma cell lines.
Lymphoma
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification and properties.
Lymphoma
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification by affinity chromatography and ultraviolet difference spectrophotometric and circular dichroic studies.
Lymphoma
Dihydrofolate reductase from the L1210 R murine lymphoma. Further studies on the binding of substrates and inhibitors to the enzyme.
Lymphoma
Dihydrofolate reductase from the L1210R murine lymphoma. Fluorometric measurements of the interaction of the enzyme with coenzymes, substrates, and inhibitors.
Lymphoma
DNA methylation alters chromatin structure and regulates Thy-1 expression in EL-4 T cells.
Lymphoma
Dynamics and longevity of the glycolipid-anchored membrane protein, Thy-1.
Lymphoma
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Lymphoma
Effect of gene dosage on cell-surface expression of Thy-1 antigen in somatic cell hybrids between Thy-1- Abelson-leukemia-virus induced lymphomas and Thy-1+ mouse lymphomas.
Lymphoma
Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.
Lymphoma
Evidence from neuron/lymphoma heterokaryons for a common trans-acting factor suppressing Thy-1 expression.
Lymphoma
Evidence that murine hematopoietic cell subset marker J11d is attached to a glycosyl-phosphatidylinositol membrane anchor.
Lymphoma
Evidence that the Thy-1 molecule is the target for T cell mitogenic antibody against brain-associated antigens.
Lymphoma
Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer.
Lymphoma
Expression of Thy-1 glycoprotein on lectin-resistant lymphoma cell lines.
Lymphoma
F1 resistance to AKR lymphoma cells in vivo and in vitro.
Lymphoma
Fatty acids regulate Thy-1 antigen mRNA stability in T lymphocyte precursors.
Lymphoma
Gene amplification in methotrexate-resistant mouse cells. I. DNA rearrangement accompanies dihydrofolate reductase gene amplification in a T-cell lymphoma.
Lymphoma
Glycoinositol phospholipid anchor-defective K562 mutants with biochemical lesions distinct from those in Thy-1- murine lymphoma mutants.
Lymphoma
High expression of the Thy-1 antigen on natural killer cells recently derived from bone marrow.
Lymphoma
Hydrophilic anchor-deficient Thy-1 is secreted by a class E mutant T lymphoma.
Lymphoma
Immunoelectron microscopic localization of Thy-1 glycoprotein in wild type and Thy-1-negative lymphoma cells.
Lymphoma
Immunogenetics of a thymus antigen in lymphoma-prone and lymphoma-resistant colonies of wild mice.
Lymphoma
Increased gamma/delta T cells and Thy-1 cells in cutaneous T cell lymphoma.
Lymphoma
Increased gene amplification in L5178Y mouse lymphoma cells with hydroxyurea-induced chromosomal aberrations.
Lymphoma
Lymphoma Thy-1 glycoprotein is linked to the cytoskeleton via a 4.1-like protein.
Lymphoma
Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo.
Lymphoma
Mannosamine inhibits the synthesis of putative glycoinositol phospholipid anchor precursors in mammalian cells without incorporating into an accumulated intermediate.
Lymphoma
Metabolic correction of defects in the lipid anchoring of Thy-1 in lymphoma mutants.
Lymphoma
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.
Lymphoma
Mitogenicity of anti-Thy-1 monoclonal antibodies attributable to an Fc-dependent mechanism.
Lymphoma
Multi-level regulation of Thy-1 antigen expression in mouse T lymphomas.
Lymphoma
Multiple activities of a cloned cell line mediating natural killer cell function.
Lymphoma
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.
Lymphoma
Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells.
Lymphoma
Radiolabeling and isolation of Thy-1 active glycolipids from murine brain and lymphoma cell lines.
Lymphoma
Regulation of Thy-1 and Pgp-1 glycoproteins in hybrids between T-cell lymphomas and Abelson-leukemia-virus-induced lymphomas.
Lymphoma
Saponin-induced release of cell-surface-anchored Thy-1 by serum glycosylphosphatidylinositol-specific phospholipase D.
Lymphoma
Sequential activation and loss of the pre-B cell Thy-1 gene in T-cell X pre-B cell somatic hybrids.
Lymphoma
Sodium butyrate causes reexpression of three membrane proteins on glycolipid-anchoring mutants.
Lymphoma
T-cell lymphomas emerging as epineoplasms in mice bearing transplanted polyoma virus-induced salivary gland tumors.
Lymphoma
The amino acid sequence of dihydrofolate reductase from the mouse lymphoma L1210.
Lymphoma
The glycophospholipid anchor of Thy-1. Biosynthetic labeling experiments with wild-type and class E Thy-1 negative lymphomas.
Lymphoma
The phenotype of five classes of T lymphoma mutants. Defective glycophospholipid anchoring, rapid degradation, and secretion of Thy-1 glycoprotein.
Lymphoma
The synthesis and properties of T25 blycoprotein in Thy-1-negative mutant lymphoma cells.
Lymphoma
The Thy-1 antigen exhibits rapid lateral diffusion in the plasma membrane of rodent lymphoid cells and fibroblasts.
Lymphoma
Thy-1 supports adhesion of mouse thymocytes to thymic epithelial cells through a Ca2(+)-independent mechanism.
Lymphoma
Thy-1 variants of mouse lymphomas: biochemical characterization of the genetic defect.
Lymphoma
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro.
Lymphoma
Transplantation of canine malignant lymphomas in the nude and SCID mouse.
Lymphoma
Trimethoprim binding to bacterial and mammalian dihydrofolate reductase: a comparison by proton and carbon-13 nuclear magnetic resonance.
Lymphoma
Variation of dihydrofolate reductase activity during in vitro and in vivo growth of sublines of L1210 lymphoma.
Lymphoma, B-Cell
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase.
Lymphoma, B-Cell
Pleiotropic loss of activation pathways in a T-cell receptor alpha-chain deletion variant of a cytolytic T-cell clone.
Lymphoma, B-Cell
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.
Lymphoma, Non-Hodgkin
A second target of benzamide riboside: Dihydrofolate reductase.
Lymphoma, Non-Hodgkin
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Lymphoma, Non-Hodgkin
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Lymphoma, Non-Hodgkin
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Lymphoma, Non-Hodgkin
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.
Lymphoma, Non-Hodgkin
The cytotoxic effect of methotrexate as evaluated by colony-forming activity of hemopoietic and tumor cells.
Lymphoma, T-Cell
A mutant lymphoma cell line with a defective Thy-1 glycoprotein gene.
Lymphoma, T-Cell
A Thy-1- mutant defining a gene acting in trans position to regulate cell-surface Thy-1 glycoprotein expression and Thy-1 messenger RNA content.
Lymphoma, T-Cell
Demonstration of a hematopoietic stem cell antigen (SC-1) on a murine lymphoma and isolation of variants lacking the antigen.
Lymphoma, T-Cell
DNA methylation alters chromatin structure and regulates Thy-1 expression in EL-4 T cells.
Lymphoma, T-Cell
Evidence that the Thy-1 molecule is the target for T cell mitogenic antibody against brain-associated antigens.
Lymphoma, T-Cell
Gene amplification in methotrexate-resistant mouse cells. I. DNA rearrangement accompanies dihydrofolate reductase gene amplification in a T-cell lymphoma.
Lymphoma, T-Cell
MG-1: a specificity identifying members of the macrophage and granulocyte lineages of mice.
Lymphoma, T-Cell
Mitogenicity of anti-Thy-1 monoclonal antibodies attributable to an Fc-dependent mechanism.
Lymphoma, T-Cell
Phenotypic drift and clonal variation in differentiation antigen expression on AKR T-cell lymphoma lines grown in vitro.
Lymphoma, T-Cell
Regulation of Thy-1 and Pgp-1 glycoproteins in hybrids between T-cell lymphomas and Abelson-leukemia-virus-induced lymphomas.
Lymphoma, T-Cell
Sequential activation and loss of the pre-B cell Thy-1 gene in T-cell X pre-B cell somatic hybrids.
Lymphoma, T-Cell, Cutaneous
Increased gamma/delta T cells and Thy-1 cells in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Peripheral
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Macular Degeneration
Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.
Macular Degeneration
Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and Migration: Implications in Neovascular Age-Related Macular Degeneration.
Malaria
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
Malaria
A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum.
Malaria
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
Malaria
A molecular surveillance system for global patterns of drug resistance in imported malaria.
Malaria
A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum.
Malaria
A new tool for the serodiagnosis of acute Plasmodium falciparum malaria in individuals with primary infection.
Malaria
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
Malaria
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.
Malaria
A transgenic Neospora caninum strain based on mutations of the dihydrofolate reductase-thymidylate synthase gene.
Malaria
Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin.
Malaria
Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence.
Malaria
Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations.
Malaria
Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast.
Malaria
Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase.
Malaria
Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model.
Malaria
Application of loop-mediated isothermal amplification assay combined with lateral flow dipstick for detection of Plasmodium falciparum and Plasmodium vivax.
Malaria
Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi.
Malaria
Basis for antifolate action and resistance in malaria.
Malaria
Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?
Malaria
Carriage of Mutant Dihydrofolate Reductase and Dihydropteroate Synthase Genes among Plasmodium falciparum Isolates Recovered from Pregnant Women with Asymptomatic Infection in Lagos, Nigeria.
Malaria
Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase.
Malaria
Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand.
Malaria
Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine.
Malaria
Chromosomal rearrangements and point mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection.
Malaria
Combinations of 4-aminobenzoic acid competitors and dihydrofolate dehydrogenase inhibitors in the chemotherapy of malaria. A commentary.
Malaria
Comparison of two nested PCR methods for the detection of human malaria.
Malaria
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers.
Malaria
Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana.
Malaria
Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.
Malaria
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.
Malaria
Decreased susceptibility to dihydrofolate reductase inhibitors associated with genetic polymorphisms in Ugandan Plasmodium falciparum isolates.
Malaria
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
Malaria
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
Malaria
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
Malaria
DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France.
Malaria
Dihydrofolate reductase and antifolate resistance in malaria.
Malaria
Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation.
Malaria
Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy.
Malaria
Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata.
Malaria
Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections.
Malaria
Discovery of traditional Chinese medicine derived compounds as wild type and mutant Plasmodium falciparum dihydrofolate reductase inhibitors: Induced fit docking and ADME studies.
Malaria
Divergent regulation of dihydrofolate reductase between malaria parasite and human host.
Malaria
Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance.
Malaria
Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.
Malaria
Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.
Malaria
Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia.
Malaria
Emergence of sulfadoxine-pyrimethamine resistance in Indian isolates of Plasmodium falciparum in the last two decades.
Malaria
Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains.
Malaria
Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in nanoro, burkina faso.
Malaria
Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.
Malaria
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.
Malaria
Fitness effects of DHFR-TS mutations associated with pyrimethamine resistance in apicomplexan parasites.
Malaria
Folate metabolism as a source of molecular targets for antimalarials.
Malaria
Functional expression of the dihydrofolate reductase and thymidylate synthetase activities of the human malaria parasite Plasmodium falciparum in Escherichia coli.
Malaria
Gametocytocidal and sporontocidal effects of antimalarial drugs on malaria parasites. II. Action of the folic reductase inhibitors, chlorguanide, and pyrimethamine against Plasmodium cynomolgi.
Malaria
Genetic evidence for Plasmodium falciparum resistance to chloroquine and pyrimethamine in Indochina and the Western Pacific between 1984 and 1998.
Malaria
Genetic variations of the dihydrofolate reductase gene of Plasmodium vivax in Mandalay Division, Myanmar.
Malaria
Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran.
Malaria
Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia.
Malaria
Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand.
Malaria
Geographical spread and structural basis of sulfadoxine-pyrimethamine drug-resistant malaria parasites.
Malaria
High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India.
Malaria
High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria.
Malaria
High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.
Malaria
High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.
Malaria
Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
Malaria
Human dihydrofolate reductase influences the sensitivity of the malaria parasite Plasmodium falciparum to ketotifen - A cautionary tale in screening transgenic parasites.
Malaria
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
Malaria
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Malaria
Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.
Malaria
Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
Malaria
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
Malaria
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi.
Malaria
Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria.
Malaria
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Malaria
Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.
Malaria
Linkage disequilibrium between two chromosomally distinct loci associated with increased resistance to chloroquine in Plasmodium falciparum.
Malaria
Linkage group selection: rapid gene discovery in malaria parasites.
Malaria
Loop-Mediated Isothermal Amplification and LFD Combination for Detection of Plasmodium falciparum and Plasmodium vivax.
Malaria
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali.
Malaria
Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes.
Malaria
Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes.
Malaria
Malaria treatment failure with novel mutation in the Plasmodium falciparum dihydrofolate reductase (pfdhfr) gene in Kolkata, West Bengal, India.
Malaria
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.
Malaria
Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors.
Malaria
Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax.
Malaria
Molecular docking analysis of phyto-constituents from Cannabis sativa with pfDHFR.
Malaria
Molecular Docking Analysis of Pyrimethamine Derivatives with Plasmodium falciparum Dihydrofolate Reductase.
Malaria
Molecular docking and QSAR studies for modeling the antimalarial activity of hybrids 4-anilinoquinoline-triazines derivatives with the wild-type and mutant receptor pf-DHFR.
Malaria
Molecular epidemiology of malaria in Cameroon. XI. Geographic distribution of Plasmodium falciparum isolates with dihydrofolate reductase gene mutations in southern and central Cameroon.
Malaria
Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles.
Malaria
Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Malaria
Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination.
Malaria
Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum.
Malaria
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
Malaria
Molecular epidemiology of Plasmodium vivax anti-folate resistance in India.
Malaria
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Malaria
Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan.
Malaria
Molecular survey of Plasmodium falciparum resistance in south-eastern Iran.
Malaria
Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210.
Malaria
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Malaria
Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries.
Malaria
New developments in malaria diagnostics: Monoclonal antibodies against Plasmodium dihydrofolate reductase-thymidylate synthase, heme detoxification protein and glutamate rich protein.
Malaria
Novel approaches to tackling malarial drug resistance using yeast.
Malaria
Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania.
Malaria
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Malaria
Plasmodium falciparum multiple infections, disease severity and host characteristics in malaria affected travellers returning from Africa.
Malaria
Plasmodium falciparum: mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient.
Malaria
Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children.
Malaria
Plasmodium vivax: Prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan.
Malaria
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis.
Malaria
Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.
Malaria
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Malaria
Polymorphisms in Plasmodium falciparum dihydropteroate synthetase and dihydrofolate reductase genes in Nigerian children with uncomplicated malaria using high-resolution melting technique.
Malaria
Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.
Malaria
Preclinical evaluation of antifolate QN254 (5-chloro-N*6*-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine) as antimalarial drug candidate.
Malaria
Prevalence of mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum: analysis of imported cases of malaria in Italy.
Malaria
Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania.
Malaria
Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon.
Malaria
Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum.
Malaria
Probing the Structural Dynamics of the Plasmodium falciparum Tunneling-Fold Enzyme 6-Pyruvoyl Tetrahydropterin Synthase to Reveal Allosteric Drug Targeting Sites.
Malaria
Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance.
Malaria
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Malaria
Purification of the bifunctional thymidylate synthase-dihydrofolate reductase complex from the human malaria parasite Plasmodium falciparum.
Malaria
Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites.
Malaria
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Malaria
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Malaria
Pyrimethamine resistant mutations in Plasmodium falciparum.
Malaria
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
Malaria
Quantitative structure-activity relationships for cycloguanil analogs as PfDHFR inhibitors using mathematical molecular descriptors.
Malaria
Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene.
Malaria
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Malaria
Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria.
Malaria
Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
Malaria
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes.
Malaria
Selection strength and hitchhiking around two anti-malarial resistance genes.
Malaria
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine.
Malaria
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
Malaria
Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance.
Malaria
Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition.
Malaria
Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum.
Malaria
Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria.
Malaria
Stable transfection of malaria parasite blood stages.
Malaria
Stepwise acquisition of pyrimethamine resistance in the malaria parasite.
Malaria
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Malaria
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Malaria
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Malaria
Targeting DHFR in parasitic protozoa.
Malaria
The chemotherapy of rodent malaria, 8. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites, part 3: the action of sulphormethoxine and pyrimethamine on the sporogonic stages.
Malaria
The chemotherapy of rodent malaria. 18. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 5. The blood schizontocidal action of some newer sulphonamides.
Malaria
The chemotherapy of rodent malaria. VI. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. I. Introduction and anti-vector studies.
Malaria
The chemotherapy of rodent malaria. VII. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites, 2: schizontocidal action in the albino mouse.
Malaria
The chemotherapy of rodent malaria. XIV. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 4. The response of normal and drug-resistant strains of Plasmodium berghei.
Malaria
The cytogenetic effects of pyrimethamine on male mouse germ cells.
Malaria
The effect of point mutations in dihydrofolate reductase genes and multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan.
Malaria
The Plasmodium falciparum, Nima-related kinase Pfnek-4: a marker for asexual parasites committed to sexual differentiation.
Malaria
The selectable marker human dihydrofolate reductase enables sequential genetic manipulation of the Plasmodium berghei genome.
Malaria
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.
Malaria
Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China- Myanmar border.
Malaria
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Malaria
Towards an understanding of drug resistance in malaria: three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building.
Malaria
Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine.
Malaria
Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.
Malaria
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Malaria
Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis.
Malaria
Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Malaria
Whole genome re-sequencing identifies a mutation in an ABC transporter (mdr2) in a Plasmodium chabaudi clone with altered susceptibility to antifolate drugs.
Malaria
[Molecular epidemiological surveillance of markers for antimalarial drugs in Plasmodium falciparum isolates imported to Barcelona, Spain]
Malaria
[Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy]
Malaria
[Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene]
Malaria
[Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia]
Malaria
[Resistance to chloroquine and cycloguanil of Plasmodium falciparum in patients arriving in France after travel in Africa without chemoprophylaxis]
Malaria, Avian
Global phylogeographic limits of Hawaii's avian malaria.
Malaria, Cerebral
Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.
Malaria, Falciparum
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
Malaria, Falciparum
Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.
Malaria, Falciparum
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.
Malaria, Falciparum
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
Malaria, Falciparum
Divergent regulation of dihydrofolate reductase between malaria parasite and human host.
Malaria, Falciparum
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
Malaria, Falciparum
Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.
Malaria, Falciparum
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Malaria, Falciparum
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Malaria, Falciparum
Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China- Myanmar border.
Malaria, Falciparum
Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine.
Malaria, Falciparum
Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.
Malaria, Falciparum
[Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene]
Malaria, Vivax
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates.
Malaria, Vivax
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.
Malaria, Vivax
Lack of quadruple and quintuple mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates from Brazilian endemic areas.
Malaria, Vivax
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Malaria, Vivax
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.
Malnutrition
Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat.
Malnutrition
Effect of protein-intake on dihydrofolate-reductase activity of host and tumor-tissues.
Marek Disease
A gene for dihydrofolate reductase in a herpesvirus.
Mastitis
Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows.
Mastocytoma
Anti-Thy-1 antibody responses evoked by Thy-1 antigen expressed in transfected mouse mastocytoma cells and rat fibroblast.
Measles
Generation of mammalian cells expressing stably measles virus proteins via bicistronic RNA.
Medulloblastoma
Dihydrofolate reductase activity in primary brain tumors in children.
Medulloblastoma
miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47.
Melanoma
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Melanoma
Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum.
Melanoma
Directed phenotype switching as an effective antimelanoma strategy.
Melanoma
Dynamic catch of a Thy-1-?5?1+syndecan-4 trimolecular complex.
Melanoma
Endogenous gene and amplifiable cDNA construct both produce unstable t-PA mRNA in Bowes melanoma cells.
Melanoma
Expression of Thy-1 antigen on human melanoma cells.
Melanoma
Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium.
Melanoma
Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.
Melanoma
Melanoma Activation of 3-O-(3,4,5-Trimethoxybenzoyl)-(-)-Epicatechin to a Potent Irreversible Inhibitor of Dihydrofolate Reductase.
Melanoma
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Melanoma
Natural resistance to methotrexate in human melanomas.
Melanoma
Synthesis and Biological Activity of a 3,4,5-Trimethoxybenzoyl Ester Analogue of Epicatechin-3-gallate.
Melanoma
The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells.
Melanoma
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Melanoma
Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.
Melanoma, Experimental
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Mesothelioma
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
Mesothelioma
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Mesothelioma, Malignant
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Monoclonal Gammopathy of Undetermined Significance
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Mucositis
Effect of local bee honey on dihydrofolate reductase enzyme inhibitor-induced mucositis: A histological study on albino wistar rats.
Multiple Myeloma
Proteomic analysis of oridonin-induced apoptosis in multiple myeloma cells.
Multiple Myeloma
The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.
Murine Acquired Immunodeficiency Syndrome
A unique subset of normal murine CD4+ T cells lacking Thy-1 is expanded in a murine retrovirus-induced immunodeficiency syndrome, MAIDS.
Muscle Weakness
The Sympathetic Nervous System Regulates Skeletal Muscle Motor Innervation and Acetylcholine Receptor Stability.
Muscular Atrophy
eNOS Uncoupling, A Therapeutic Target For Ischemic Foot of Diabetic Rat.
Muscular Dystrophy, Duchenne
Two expressed human genes sustain slightly more DNA damage after alkylating agent treatment than an inactive gene.
Mycosis Fungoides
Cutaneous expression of Thy-1 in mycosis fungoides.
Mycosis Fungoides
Thy-1 and T-cell receptor antigen expression in mycosis fungoides and benign inflammatory dermatoses.
Myelodysplastic Syndromes
Cytochemical study of tetrahydrofolate dehydrogenase in myelodysplastic syndromes.
Myelodysplastic Syndromes
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Myelodysplastic Syndromes
Qualitative and quantitative study of dihydrofolate reductase in myelodysplastic syndromes.
Nasopharyngeal Carcinoma
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Neoplasm Metastasis
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Neoplasm Metastasis
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Neoplasm Metastasis
Expression of Thy-1 antigen on human melanoma cells.
Neoplasm Metastasis
Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells.
Neoplasm Metastasis
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats.
Neoplasm Metastasis
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.
Neoplasm Metastasis
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Neoplasm Metastasis
Mechanisms of methotrexate resistance in osteosarcoma.
Neoplasm Metastasis
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Neoplasm Metastasis
Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy.
Neoplasm Metastasis
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Neoplasm Metastasis
Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton.
Neoplasm Metastasis
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.
Neoplasm Metastasis
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Neoplasm Metastasis
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Neoplasm Metastasis
The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells.
Neoplasm Metastasis
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Neoplasm Metastasis
Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
Neoplasm Metastasis
Thy-1 in Integrin Mediated Mechanotransduction.
Neoplasm Metastasis
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Neoplasms
10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
Neoplasms
2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.
Neoplasms
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.
Neoplasms
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
Neoplasms
A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate.
Neoplasms
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Neoplasms
A Daily Dose of 5 mg Folic Acid for 90 Days Is Associated with Increased Serum Unmetabolized Folic Acid and Reduced Natural Killer Cell Cytotoxicity in Healthy Brazilian Adults.
Neoplasms
A new form of dihydrofolate reductase in cancer cells.
Neoplasms
A one-pot analysis approach to simplify measurements of protein stability and folding kinetics.
Neoplasms
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Neoplasms
A polycistronic transcript in transformed cells encodes the dihydrofolate reductase of herpesvirus saimiri.
Neoplasms
A rapid method for separating tumour infiltrating cells and tumour cells from colorectal tumours.
Neoplasms
A second target of benzamide riboside: Dihydrofolate reductase.
Neoplasms
A Tribute to Bruce Chabner.
Neoplasms
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Neoplasms
Aberrant Expression of Folate Metabolism Enzymes and Its Diagnosis and Survival Prediction in Ovarian Carcinoma.
Neoplasms
Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosarcoma xenografts.
Neoplasms
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in ?16HER2 transgenic mice.
Neoplasms
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.
Neoplasms
Analogues of methotrexate and aminopterin with gamma-methylene and gamma-cyano substitution of the glutamate side chain: synthesis and in vitro biological activity.
Neoplasms
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Neoplasms
Analysis of dihydrofolate reductase gene amplification in a methotrexate-resistant human tumor cell line.
Neoplasms
Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method.
Neoplasms
Anticancer properties of distinct antimalarial drug classes.
Neoplasms
Antifolate agents: a patent review (2010 - 2013).
Neoplasms
Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Neoplasms
Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats.
Neoplasms
Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Neoplasms
Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Neoplasms
Binding of natural and synthetic polyphenols to human dihydrofolate reductase.
Neoplasms
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Neoplasms
Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.
Neoplasms
Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Neoplasms
Biosynthetic and structural studies on Thy-1 in a rat neuronal tumor cell line.
Neoplasms
Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Neoplasms
c-Myc dependent initiation of genomic instability during neoplastic transformation.
Neoplasms
c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo.
Neoplasms
Cancer research: from folate antagonism to molecular targets.
Neoplasms
CD90 and CD24 Co-Expression Is Associated with Pancreatic Intraepithelial Neoplasias.
Neoplasms
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.
Neoplasms
Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture.
Neoplasms
Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Neoplasms
Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
Neoplasms
Central nervous system pharmacology of Baker's antifolate (NSC139105) in man.
Neoplasms
Chapter 9 regulation of human dihydrofolate reductase activity and expression.
Neoplasms
Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities.
Neoplasms
Characterization of tumor-associated lymphocytes in a series of mouse mammary tumor lines with differing biological properties.
Neoplasms
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
Neoplasms
CNT-based nanocarrier loaded with pyrimethamine for adipose mesenchymal stem cells differentiation and cancer treatment: The computational and experimental methods.
Neoplasms
Co-expression and amplification of dihydrofolate reductase cDNA and the Escherichia coli XGPRT gene in Chinese hamster ovary cells.
Neoplasms
Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.
Neoplasms
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Neoplasms
Construction of a dominant selectable marker using a novel dihydrofolate reductase.
Neoplasms
Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness.
Neoplasms
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Neoplasms
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Neoplasms
Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema.
Neoplasms
Daily supplementation with 5 mg of folic acid in Brazilian patients with hereditary spherocytosis.
Neoplasms
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
Neoplasms
Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.
Neoplasms
Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study.
Neoplasms
Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic.
Neoplasms
Design and rationale for novel antifolates.
Neoplasms
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.
Neoplasms
Design of dihydrofolate reductase inhibitors from X-ray crystal structures.
Neoplasms
Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase.
Neoplasms
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
Neoplasms
Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
Neoplasms
Determination of plasma trimetrexate levels using gas chromatography-mass spectrometry with selected-ion monitoring.
Neoplasms
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Neoplasms
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Neoplasms
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
Neoplasms
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.
Neoplasms
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Neoplasms
Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.
Neoplasms
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Neoplasms
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Neoplasms
Dihydrofolate reductase and cell growth activity inhibition by the beta-carboline-benzoquinolizidine plant alkaloid deoxytubulosine from Alangium lamarckii: its potential as an antimicrobial and anticancer agent.
Neoplasms
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Neoplasms
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes.
Neoplasms
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Neoplasms
Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.
Neoplasms
DNA damage and repair measured in different genomic regions using the comet assay with fluorescent in situ hybridization.
Neoplasms
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Neoplasms
DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia.
Neoplasms
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Neoplasms
Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Neoplasms
Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.
Neoplasms
Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
Neoplasms
Effect of protein-intake on dihydrofolate-reductase activity of host and tumor-tissues.
Neoplasms
Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells.
Neoplasms
Effects of PSK, an antitumor protein-bound polysaccharide, on the surface charge of lymphocytes in X5563-bearing mice.
Neoplasms
Effects of trimethoprim on leukaemic cells in vitro.
Neoplasms
Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.
Neoplasms
Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.
Neoplasms
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Neoplasms
Enzymes of the one-carbon folate metabolism as anticancer targets predicted by survival rate analysis.
Neoplasms
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Neoplasms
Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Neoplasms
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Neoplasms
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Neoplasms
Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress.
Neoplasms
Expression of Ly-6.2 and Thy-1 antigens on NIH 3T3 cells suppressed after transformation with activated human ras-oncogenes.
Neoplasms
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Neoplasms
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Neoplasms
Expression of Thy-1 and effect of phosphatidylinositol-specific phospholipase C on primate and murine cell lines.
Neoplasms
Expression of Thy-1 antigen on human melanoma cells.
Neoplasms
Folate analogues. 21. Synthesis and antifolate and antitumor activities of N10-(cyanomethyl)-5,8-dideazafolic acid.
Neoplasms
Formation, turnover, and sensitivity to phosphatidylinositol-specific phospholipase C of Thy-1 of a rat neuronal tumor cell line.
Neoplasms
Further studies on substituted quinazolines and triazines as inhibitors of a methotrexate-insensitive murine dihydrofolate reductase.
Neoplasms
Gene amplification: an example of accelerated evolution in tumorigenic cells.
Neoplasms
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
Neoplasms
Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines.
Neoplasms
Gene-specific DNA repair of pyrimidine dimers does not decline during cellular aging in vitro.
Neoplasms
Genotoxicity of pemetrexed in human peripheral blood lymphocytes.
Neoplasms
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
Neoplasms
Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids.
Neoplasms
Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy.
Neoplasms
Heterogeneity of methotrexate binding in human colon tumor cells.
Neoplasms
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Neoplasms
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Neoplasms
Highly inducible synthesis of heterologous proteins in epithelial cells carrying a glucocorticoid-responsive vector.
Neoplasms
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Neoplasms
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Neoplasms
Human embryonic and neuronal stem cell markers in retinoblastoma.
Neoplasms
Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.
Neoplasms
Identification of a cis-acting element of human dihydrofolate reductase mRNA.
Neoplasms
Identification of dihydrofolate reductase in human central-nervous-system tumours.
Neoplasms
Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.
Neoplasms
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Neoplasms
Identification of three new compounds that directly target human serine hydroxymethyltransferase 2.
Neoplasms
Immunogenetics of a thymus antigen in lymphoma-prone and lymphoma-resistant colonies of wild mice.
Neoplasms
Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines.
Neoplasms
Immunologic basis of resistance to RL male 1 induced by immunoselected Thy-1.2 negative variants.
Neoplasms
Immunophenotype profile of childhood medulloblastomas and supratentorial primitive neuroectodermal tumors using 16 monoclonal antibodies.
Neoplasms
Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies.
Neoplasms
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
Neoplasms
In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics.
Neoplasms
In vitro and in vivo interaction between murine fibrosarcoma cells and natural killer cells.
Neoplasms
In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.
Neoplasms
In vivo methotrexate transport in murine Lewis lung tumor.
Neoplasms
Increased levels of multiple forms of dihydrofolate reductase in peripheral blood leucocytes of cancer patients receiving haematopoietic colony-stimulating factors: interim analysis.
Neoplasms
Increasing Methotrexate Resistance by Combination of Active-site Mutations in Human Dihydrofolate Reductase.
Neoplasms
Induction of CD4(+)CD25(+)Foxp3(-) regulatory T cells by Thy-1 stimulation of CD4(+) T cells.
Neoplasms
Induction of white cell proliferation due to haematopoietic growth factors is associated with an increase in multiple forms of dihydrofolate reductase in non-neutropenic cancer patients.
Neoplasms
Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity.
Neoplasms
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Neoplasms
Inhibition of dihydrofolate reductase. 3. 4.6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor enzymes.
Neoplasms
Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
Neoplasms
Inhibition of human dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s. A quantitative structure-activity relationship analysis.
Neoplasms
Inhibition of in vitro generation of cytotoxicity against tumor cells by monoclonal antibody to Thy-1.
Neoplasms
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Neoplasms
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
Neoplasms
Intracellular Ca2+ Increases and Connexin 43 Hemichannel Opening Are Necessary but Not Sufficient for Thy-1-Induced Astrocyte Migration.
Neoplasms
Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Neoplasms
Investigations on the biological properties of the lipophilic DHFR-inhibitory benzoprims reveal non-folate modes of action and opportunities for anti-cancer drug design.
Neoplasms
Irreversible enzyme inhibitors. 118. Hydrophobic bonding to dihydrofolic reductase. XII. Further comparisons with the enzyme from Walker 256 rat tumor and rat liver.
Neoplasms
K20 and ICO-10 monoclonal antibodies (gp120/200; Thy-1): immunophenotyping of human solid tumours.
Neoplasms
Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.
Neoplasms
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Neoplasms
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.
Neoplasms
Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
Neoplasms
Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.
Neoplasms
Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs.
Neoplasms
Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
Neoplasms
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.
Neoplasms
Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
Neoplasms
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Neoplasms
Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo.
Neoplasms
Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Neoplasms
Mechanism of inhibition of wt-dihydrofolate reductase from E. coli by tea epigallocatechin-gallate.
Neoplasms
Mechanism-based design, synthesis and biological studies of N?-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents.
Neoplasms
Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.
Neoplasms
Mechanisms of methotrexate resistance in osteosarcoma.
Neoplasms
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Neoplasms
Membrane phenotype of the rat cytotoxic T lymphocyte.
Neoplasms
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Neoplasms
Methotrexate analogues. 29. Effect of gamma-aminobutyric acid spacers between the pteroyl and glutamate moieties on enzyme binding and cell growth inhibition.
Neoplasms
Methotrexate analogues. 30. Dihydrofolate reductase inhibition and in vitro tumor cell growth inhibition by N epsilon-(haloacetyl)-L-lysine and N delta-(haloacetyl)-L-ornithine analogues and an acivicin analogue of methotrexate.
Neoplasms
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
Neoplasms
Methotrexate and folic reductase in human cancer.
Neoplasms
Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model.
Neoplasms
Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate.
Neoplasms
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Neoplasms
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
Neoplasms
Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton.
Neoplasms
Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2.
Neoplasms
Methotrexate polyglutamate synthesis by cultured human breast cancer cells.
Neoplasms
Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.
Neoplasms
Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
Neoplasms
Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells.
Neoplasms
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Neoplasms
Mitochondrial One-Carbon Pathway Supports Cytosolic Folate Integrity in Cancer Cells.
Neoplasms
Mitogenic hormones and tumor promoters greatly increase the incidence of colony-forming cells bearing amplified dihydrofolate reductase genes.
Neoplasms
Modulation and biological effects of Ly-6.2 expression on EL4 tumour cells.
Neoplasms
Modulation of CD4 expression on lymphoma cells transplanted to mice fed (n - 3) polyunsaturated fatty acids.
Neoplasms
Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.
Neoplasms
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Neoplasms
Much more than you expected: The non-DHFR-mediated effects of methotrexate.
Neoplasms
Multidrug resistance and its reversal.
Neoplasms
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Neoplasms
Natural resistance to methotrexate in human melanomas.
Neoplasms
New agents for colon and breast cancer.
Neoplasms
New antifolates in clinical development.
Neoplasms
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
Neoplasms
Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: bridge modifications and heterocyclic benzoyl isosters of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate.
Neoplasms
Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: Design, synthesis and antifolate activity.
Neoplasms
Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
Neoplasms
Novel high-performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma-methylene-10-deazaaminopterin and its major metabolite, 7-hydroxy-gamma-methylene-10-deazaaminopterin, in patients with solid cancers in a phase I trial.
Neoplasms
Occurrence and significance of D-methotrexate as a contaminant of commercial methotrexate.
Neoplasms
One-carbon genetic variants and the role of MTHFD1 1958G>A in liver and colon cancer risk according to global DNA methylation.
Neoplasms
Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer.
Neoplasms
Oral piritrexim, an effective treatment for metastatic urothelial cancer.
Neoplasms
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Neoplasms
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Neoplasms
Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats.
Neoplasms
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Neoplasms
Phase I studies of trimetrexate using single and weekly dose schedules.
Neoplasms
Phase I studies with Baker's Antifol (BAF) (NSC 139105).
Neoplasms
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Neoplasms
Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Neoplasms
Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactions.
Neoplasms
Phorbol ester dramatically increases incidence of methotrexate-resistant mouse cells: possible mechanisms and relevance to tumor promotion.
Neoplasms
Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.
Neoplasms
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy.
Neoplasms
Piritrexim (ILEX Oncology).
Neoplasms
Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.
Neoplasms
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Neoplasms
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Neoplasms
Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA.
Neoplasms
Potential anticancer agents. XXIII. 1. Qualitative structure--activity relationship in the "classical" antifolates area.
Neoplasms
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Neoplasms
Prognostic Significance of miR-215 in Colon Cancer.
Neoplasms
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Neoplasms
Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells.
Neoplasms
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
Neoplasms
Quantitation of dihydrofolate reductase and thymidylate synthase mRNAs in vivo and in vitro by polymerase chain reaction.
Neoplasms
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
Neoplasms
Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines.
Neoplasms
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.
Neoplasms
Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Neoplasms
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Neoplasms
Resistance proteins in human kidney, breast, ovarian and lung-carcinoma - a comparative-analysis.
Neoplasms
Risk Stratification in Multinodular Goiter: A Retrospective Review of Sonographic Features, Histopathological Results, and Cancer Risk.
Neoplasms
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Neoplasms
Role of E2F-1 in chemosensitivity.
Neoplasms
Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.
Neoplasms
Role of the cellular oxidation-reduction state in methotrexate binding to dihydrofolate reductase and dissociation induced by reduced folates.
Neoplasms
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Neoplasms
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Neoplasms
Screening of DHFR-binding drugs by MALDI-TOFMS.
Neoplasms
Second generation sequencing of the mesothelioma tumor genome.
Neoplasms
Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.
Neoplasms
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
Neoplasms
Sequence analysis of a human gene responsible for drug resistance: a rapid method for manual and automated direct sequencing of products generated by the polymerase chain reaction.
Neoplasms
Simple and Reliable HPLC Method for the Monitoring of Methotrexate in Osteosarcoma Patients.
Neoplasms
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Neoplasms
Species-specific differences in translational regulation of dihydrofolate reductase.
Neoplasms
Spontaneous nonthymic T cell lymphomas in young Wistar rats.
Neoplasms
Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc.
Neoplasms
Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities and suggests repurposing possibilities.
Neoplasms
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Neoplasms
Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.
Neoplasms
Structural Exploration and Conformational Transitions in MDM2 upon DHFR Interaction from Homo sapiens: A Computational Outlook for Malignancy via Epigenetic Disruption.
Neoplasms
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.
Neoplasms
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Neoplasms
Structural tuning of acridones for developing anticancer agents targeting dihydrofolate reductase.
Neoplasms
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution.
Neoplasms
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Neoplasms
Studies on folic reductase. 3. The level of enzyme activity and response to methotrexate of transplantable mouse tumors.
Neoplasms
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Neoplasms
Synergistic computational and experimental proteomics approaches for more accurate detection of active serine hydrolases in yeast.
Neoplasms
Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo.
Neoplasms
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
Neoplasms
Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogues of aminopterin and methotrexate.
Neoplasms
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Neoplasms
Synthesis and evaluation of 2,4-diaminoquinazoline antifolates with activity against methotrexate-resistant human tumor cells.
Neoplasms
Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain.
Neoplasms
Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Neoplasms
Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
Neoplasms
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
Neoplasms
Synthesis, Antifolate and Anticancer Activities of N(5) -Substituted 8,10-Dideazatetrahydrofolate Analogues.
Neoplasms
T-cell differentiative capacity of haematopoietic stem cells immortalized in vitro with radiation leukemia virus.
Neoplasms
Targeted Mitochondrial Fluorescence Imaging-Guided Tumor Antimetabolic Therapy with the Imprinted Polymer Nanomedicine Capable of Specifically Recognizing Dihydrofolate Reductase.
Neoplasms
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis.
Neoplasms
The 2-desamino and 2-desamino-2-methyl analogues of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture.
Neoplasms
The antifolate activity of tea catechins.
Neoplasms
The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients.
Neoplasms
The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine.
Neoplasms
The methotrexate story: a paradigm for development of cancer chemotherapeutic agents.
Neoplasms
The multiple roles of Thy-1 in cell differentiation and regeneration.
Neoplasms
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
Neoplasms
Theory and normal-mode analysis of change in protein vibrational dynamics on ligand binding.
Neoplasms
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer.
Neoplasms
THY-1 (CD90) expression promotes the growth of gastric cancer cells.
Neoplasms
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Neoplasms
Thy-1 antigen on normal and neoplastic rat mammary tissues: changes in location and amount of antigen during differentiation of cultured stem cells.
Neoplasms
Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts.
Neoplasms
Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors.
Neoplasms
Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
Neoplasms
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Neoplasms
Thy-1 inhibits mitogen-induced Ca2+ oscillation in ras-transformed mouse fibroblasts.
Neoplasms
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Neoplasms
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.
Neoplasms
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
Neoplasms
Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines.
Neoplasms
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Neoplasms
Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas.
Neoplasms
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Neoplasms
Transgenic rescue of methotrexate-induced teratogenicity in Drosophila melanogaster.
Neoplasms
Translational research with pemetrexed in breast cancer.
Neoplasms
Transplantable polyomavirus-induced salivary gland epitheliomas are populated by immature T cells derived from the host.
Neoplasms
Transplantation of canine malignant lymphomas in the nude and SCID mouse.
Neoplasms
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Neoplasms
Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
Neoplasms
Trimetrexate: clinical development of a nonclassical antifolate.
Neoplasms
Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats.
Neoplasms
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Neoplasms
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Neoplasms
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Neoplasms
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
Neoplasms
Vibrational softening of a protein on ligand binding.
Neoplasms
Vitamin B17 Ameliorates Methotrexate-Induced Reproductive Toxicity, Oxidative Stress, and Testicular Injury in Male Rats.
Neoplasms
[A preliminary study on molecular target identification of drugs in individualized treatment of malignant solid tumors in children].
Neoplasms
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
Neoplasms
[Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"]
Neoplasms
[Cotransduction of Human mdr-1 and Dihydrofolate Reductase Genes into Murine Hematopoietic Cells]
Neoplasms
[Evaluation of biochemical criteria for sensitivity of tumor cells to methotrexate by means of mathematic simulation]
Neoplasms
[Preliminary research of hepatocarcinoma stem cell markers.]
Neoplasms
[The biological behavior of hepatocarcinoma stem cells in rats]
Neoplasms, Glandular and Epithelial
[Tetrahydrofolic-dependent enzymes and dihydrofolic reductase in normal and psoriasic human epidermis and in cutaneous epithelial neoplasms]
Nephritis
Activating transcription factor 3 (ATF3) promotes sublytic C5b-9-induced glomerular mesangial cells apoptosis through up-regulation of Gadd45? and KLF6 gene expression.
Nephritis
Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis.
Nephritis
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Nephritis
Anti-mouse mesangial cell serum induces acute glomerulonephropathy in mice.
Nephritis
Anti-Thy-1 monoclonal antibody with specific reactivity with vascular endothelial cells in rat glomeruli.
Nephritis
Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies.
Nephritis
Apoptosis of glomerular mesangial cells induced by sublytic C5b-9 complexes in rats with Thy-1 nephritis is dependent on Gadd45 gamma upregulation.
Nephritis
C1q, a subunit of the first component of complement, enhances antibody-mediated apoptosis of cultured rat glomerular mesangial cells.
Nephritis
C5a Induces the Synthesis of IL-6 and TNF-? in Rat Glomerular Mesangial Cells through MAPK Signaling Pathways.
Nephritis
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Nephritis
Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis.
Nephritis
Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti-Thy-1 antibodies.
Nephritis
Eicosapentaenoic acid regulates I?B? and prevents tubulointerstitial injury in kidney.
Nephritis
Exogenous 5'-nucleotidase improves glomerular autoregulation in Thy-1 nephritic rats.
Nephritis
Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation.
Nephritis
Gene expression profile and overexpression of apoptosis-related genes (NGFI-B and Gadd 45 gamma) in early phase of Thy-1 nephritis model.
Nephritis
Glomerular damage in experimental proliferative glomerulonephritis under glomerular capillary hypertension.
Nephritis
Glomerulosclerosis develops in Thy-1 nephritis under persistent accumulation of macrophages.
Nephritis
Inhibition of Inducible Nitric Oxide Synthase Alters Thy-1 Glomeruonephritis in Rats.
Nephritis
Interferon-beta Reduces Proteinuria in Experimental Glomerulonephritis.
Nephritis
Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats.
Nephritis
KLF6 Acetylation Promotes Sublytic C5b-9-Induced Production of MCP-1 and RANTES in Experimental Mesangial Proliferative Glomerulonephritis.
Nephritis
Local actions of endogenous angiotensin II in injured glomeruli.
Nephritis
Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.
Nephritis
Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-1 nephritis.
Nephritis
Overexpression of cyclooxygenase-2 predisposes to podocyte injury.
Nephritis
Oxidant stress in hyperlipidemia-induced renal damage.
Nephritis
Participation of endothelial cells and transformed mesangial cells in remodeling of glomerular capillary loops in Thy-1 nephritis.
Nephritis
Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis.
Nephritis
Protective effects of Shichimotsu-koka-To on irreversible Thy-1 nephritis.
Nephritis
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Nephritis
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Nephritis
SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Nephritis
Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.
Nephritis
Sublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation.
Nephritis
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis Through miR-3546/SOX4/Survivin Axis in Rat Thy-1 Nephritis.
Nephritis
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis through the Cascade Pathway of MEKK2-p38 MAPK-IRF-1-TRADD-Caspase 8 in Rat Thy-1 Nephritis.
Nephritis
Sublytic C5b-9 induces glomerular mesangial cell proliferation via ERK1/2-dependent SOX9 phosphorylation and acetylation by enhancing Cyclin D1 in rat Thy-1 nephritis.
Nephritis
Sublytic C5b-9 Induces IL-23 and IL-36a Production by Glomerular Mesangial Cells via PCAF-Mediated KLF4 Acetylation in Rat Thy-1 Nephritis.
Nephritis
Sublytic C5b-9 induces IL-6 and TGF-?1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBP? acetylation.
Nephritis
Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.
Nephritis
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis in rat Thy-1 nephritis via Gadd45 activation mediated by Egr-1 and p300-dependent ATF3 acetylation.
Nephritis
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation.
Nephritis
Sublytic C5b-9 triggers glomerular mesangial cell proliferation via enhancing FGF1 and PDGF? gene transcription mediated by GCN5-dependent SOX9 acetylation in rat Thy-1 nephritis.
Nephritis
The complement C5b-9 complexes induced injury of glomerular mesangial cells in rats with Thy-1 nephritis by increasing nitric oxide synthesis.
Nephritis
The profile of gene expression and role of nuclear factor kappa B on glomerular injury in rats with Thy-1 nephritis.
Nephritis
Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.
Nephritis
Thy-1-mediated phosphatidylinositol turnover in cultured rat glomerular mesangial cell.
Nephritis
TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.
Nephritis
Tubulointerstitial injury of Thy-1 nephritis in uninephrectomized stroke-prone spontaneously hypertensive rats.
Nephritis
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Nephroma, Mesoblastic
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Neural Tube Defects
A dihydrofolate reductase 2 (DHFR2) variant is associated with risk of neural tube defects in an Irish cohort but not in a United Kingdom cohort.
Neural Tube Defects
Association of FOLH1, DHFR, and MTHFR gene polymorphisms with susceptibility of Neural Tube Defects: A case control study from Eastern India.
Neural Tube Defects
Maternal association and influence of DHFR 19?bp deletion variant predisposes foetus to anencephaly susceptibility: a family-based triad study.
Neurilemmoma
Distribution of Thy-1 differentiation alloantigen in the rat nervous system and in a cell line derived from a rat peripheral neurinoma.
Neuroblastoma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Neuroblastoma
Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors.
Neuroblastoma
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Neuroblastoma
Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]
Neuroblastoma
Distribution of the thy-1 antigen in cellular and subcellular fractions of adult mouse brain.
Neuroblastoma
Immunohistochemical performance testing of monoclonal antibodies to neuroblastoma cells on normal adrenals, spinal and sympathetic ganglia, and neural crest tumours.
Neuroblastoma
Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture.
Neuroblastoma
Role of human chromosome 11 in determining surface antigenic phenotype of normal and malignant cells. Somatic cell genetic analysis of eight antigens, including putative human Thy-1.
Neuroblastoma
Second messenger-induced modulation of Thy-1 antigen expression: an ELISA study using murine thymic and neuroblastoma cells.
Neurodegenerative Diseases
20S proteasome mediated degradation of DHFR: implications in neurodegenerative disorders.
Neurodegenerative Diseases
Genetics and Epigenetics of One-Carbon Metabolism Pathway in Autism Spectrum Disorder: A Sex-Specific Brain Epigenome?
Neuroectodermal Tumors, Primitive
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Neuroectodermal Tumors, Primitive, Peripheral
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Neutropenia
Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Neutropenia
Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
Obesity
Low folate intake and serum levels are associated with higher body mass index and abdominal fat accumulation: a case control study.
Obesity
Thy-1 (CD90) promotes bone formation and protects against obesity.
Obesity
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
Opportunistic Infections
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Opportunistic Infections
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Opportunistic Infections
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Opportunistic Infections
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.
Opportunistic Infections
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
Opportunistic Infections
In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
Opportunistic Infections
Prediction of residues involved in inhibitor specificity in the dihydrofolate reductase family.
Opportunistic Infections
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Opportunistic Infections
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Optic Nerve Injuries
Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.
Optic Nerve Injuries
Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells.
Optic Nerve Injuries
Protection by an Oral Disubstituted Hydroxylamine Derivative against Loss of Retinal Ganglion Cell Differentiation following Optic Nerve Crush.
Orbital Diseases
Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Osteoporosis
Thy-1 (CD90) promotes bone formation and protects against obesity.
Osteosarcoma
A second target of benzamide riboside: Dihydrofolate reductase.
Osteosarcoma
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Osteosarcoma
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma.
Osteosarcoma
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
Osteosarcoma
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
Osteosarcoma
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Osteosarcoma
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Osteosarcoma
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.
Osteosarcoma
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Osteosarcoma
Modulation of Sp1-dependent transcription by a cis-acting E2F element in dhfr promoter.
Osteosarcoma
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Ovarian Neoplasms
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Ovarian Neoplasms
Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer.
Ovarian Neoplasms
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
Ovarian Neoplasms
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Ovarian Neoplasms
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Ovarian Neoplasms
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Ovarian Neoplasms
[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Pancytopenia
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Pancytopenia
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Papilloma
Selective amplification in methotrexate-resistant mouse cells of an artificial dihydrofolate reductase transcription unit making use of cryptic splicing and polyadenylation sites.
Paraproteinemias
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Parasitemia
High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.
Parasitemia
Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus.
Parasitemia
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Parasitemia
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections.
Parkinson Disease
Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice.
Pemphigoid, Bullous
A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts.
Peripheral Nerve Injuries
Adhesion molecule L1 overexpressed under the control of the neuronal Thy-1 promoter improves myelination after peripheral nerve injury in adult mice.
Persistent Infection
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis.
Phenylketonurias
Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency.
Phenylketonurias
Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency.
Phenylketonurias
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Pheochromocytoma
Nerve growth factor activates Thy-1 and neurofilament gene transcription in rat PC12 cells.
Plague
Molecular Modeling Studies of Yersinia pestis Dihydrofolate Reductase.
Plasmacytoma
A Thy-1 negative lymphoma cell variant defective in the formation of glycosyl-phosphatidylinositol membrane protein anchors.
Plasmacytoma
c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo.
Plasmacytoma
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Pneumocystis Infections
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Pneumocystis Infections
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Pneumonia
A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase.
Pneumonia
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Pneumonia
Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes (dagger) (double dagger).
Pneumonia
Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Pneumonia
Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction.
Pneumonia
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Pneumonia
Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan.
Pneumonia
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
Pneumonia
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal.
Pneumonia
Genetic diversity of drug targets including dihydropteroate synthase, dihydrofolate reductase and cytochrome b, in Pneumocystis carinii f. sp. hominis isolates in Japan.
Pneumonia
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Pneumonia
Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda.
Pneumonia
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.
Pneumonia
Non specific PCR products using rat-derived Pneumocystis carinii dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples.
Pneumonia
Polymorphisms involving the Pneumocystis jirovecii-related genes in AIDS patients in eastern China.
Pneumonia
Structural studies on bioactive compounds. Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii.
Pneumonia
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Pneumonia, Pneumocystis
A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase.
Pneumonia, Pneumocystis
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Pneumonia, Pneumocystis
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Pneumonia, Pneumocystis
Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase.
Pneumonia, Pneumocystis
Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Pneumonia, Pneumocystis
Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction.
Pneumonia, Pneumocystis
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Pneumonia, Pneumocystis
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Pneumonia, Pneumocystis
Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan.
Pneumonia, Pneumocystis
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
Pneumonia, Pneumocystis
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal.
Pneumonia, Pneumocystis
Genetic diversity of drug targets including dihydropteroate synthase, dihydrofolate reductase and cytochrome b, in Pneumocystis carinii f. sp. hominis isolates in Japan.
Pneumonia, Pneumocystis
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.
Pneumonia, Pneumocystis
Polymorphisms involving the Pneumocystis jirovecii-related genes in AIDS patients in eastern China.
Pneumonia, Pneumocystis
Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.
Pneumonia, Pneumocystis
Structural studies on bioactive compounds. Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii.
Pneumonia, Pneumocystis
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A second target of benzamide riboside: Dihydrofolate reductase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotypic differences between putative hematopoietic stem cells and childhood B-cell precursor acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Resistance mechanisms to methotrexate in tumors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Resistance Mechanisms to Methotrexate in Tumors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tetrahydrofolate dehydrogenase cytochemistry in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Utilization of an immunostaining technique to demonstrate heterogeneity in the content of dihydrofolate reductase in peripheral blast cells from a patient with acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Expression and clinical significance of resistance proteins in initial acute lymphatic leukemia (ALL) in childhood]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Pregnancy, Tubal
Contribution of genetic polymorphism of methylene tetrahydrofolate reductase on the effect of methotrexate in ectopic pregnancy patients.
Primary Myelofibrosis
Blood leucocyte enzymes. II. Activities at 8-9 a.m. in cells of normal subjects, chronic lymphatic leukaemia and chronic myeloid leukaemia patients.
Prion Diseases
Decreased cell surface prion protein in mouse models of prion disease.
Prion Diseases
GPI-anchor signal sequence influences PrPC sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice.
Proteinuria
Interferon-beta Reduces Proteinuria in Experimental Glomerulonephritis.
Proteinuria
Long-term observation of glomerulonephritis induced by multiple injections with anti-Thy-1 antibody in rats.
Proteinuria
The profile of gene expression and role of nuclear factor kappa B on glomerular injury in rats with Thy-1 nephritis.
Psoriasis
A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
Psoriasis
Generalized pustular psoriasis induced by potassium iodide. A postulated role for dihydrofolic reductase.
Psoriasis
Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptor Thy-1 (CD90).
Psoriasis
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy.
Psoriasis
The antifolate activity of tea catechins.
Psoriasis
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].
Pulmonary Fibrosis
Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.
Pulmonary Fibrosis
The multiple roles of Thy-1 in cell differentiation and regeneration.
Pulmonary Fibrosis
Thy-1 depletion and integrin ?3 upregulation-mediated PI3K-Akt-mTOR pathway activation inhibits lung fibroblast autophagy in lipopolysaccharide-induced pulmonary fibrosis.
Pulmonary Fibrosis
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.
Pulmonary Fibrosis
[Effect and mechanism of inhibition of lipopolysaccharide-induced pulmonary fibrosis by butyric acid].
Rabies
Interscience conference on antimicrobial agents and chemotherapy - 50th annual meeting - research on promising new agents: part 1.
Respiratory Distress Syndrome
Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.
Respiratory Tract Infections
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Restless Legs Syndrome
Gender-specific regulation of tyrosine hydroxylase in thymocyte differentiation antigen-1 knockout mice.
Retinoblastoma
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Retinoblastoma
Excessive folic acid intake and relation to adverse health outcome.
Retinoblastoma
Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Retinoblastoma
Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.
Retinoblastoma
Quantitative evaluation of the cell cycle-related retinoblastoma protein and localization of Thy-1 differentiation protein and macrophages during follicular development and atresia, and in human corpora lutea.
Retinoblastoma
Regulation of the cancer cell membrane lipid composition by NaCHOleate: Effects on cell signaling and therapeutical relevance in glioma.
Retinoblastoma
Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia.
Retinoblastoma
Resistance mechanisms to methotrexate in tumors.
Retinoblastoma
Resistance Mechanisms to Methotrexate in Tumors.
Retinoblastoma
Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter.
Retinoblastoma
Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake.
Rhinitis, Allergic
Analysis of expression of ILC2 cells in nasal mucosa based on animal model of allergic bacterial infection rhinitis.
Riboflavin Deficiency
The effect of riboflavin deficiency on methylenetetrahydrofolate reductase (NADPH) (EC 1.5.1.20) and folate metabolism in the rat.
Sarcoma
Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Sarcoma
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.
Sarcoma
Construction and use of a dominant, selectable marker: a Harvey sarcoma virus-dihydrofolate reductase chimera.
Sarcoma
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells.
Sarcoma
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Sarcoma
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Sarcoma
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Sarcoma
Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines.
Sarcoma
Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Sarcoma
Micro-Edman degradation: the use of high pressure liquid chromatography and gas chromatography in the amino terminal sequence determination of 8 nanomoles of dihydrofolate reductase from a mouse sarcoma.
Sarcoma
Structure of amplified normal and variant dihydrofolate reductase genes in mouse sarcoma S180 cells.
Sarcoma
Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts.
Sarcoma
Thy-1 epitopes are expressed on murine myeloid leukemia and reticulum sarcoma cells.
Sarcoma
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Sarcoma, Avian
An intragenic region downstream from the dihydrofolate reductase promoter is required for replication-dependent expression.
Sarcoma, Avian
Cosmid vectors for high efficiency DNA-mediated transformation and gene amplification in mammalian cells: studies with the human growth hormone gene.
Sarcoma, Avian
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Sarcoma, Avian
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
Sarcoma, Avian
Proximal upstream flanking sequences direct calcium regulation of the rat prolactin gene.
Sarcoma, Clear Cell
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Sarcoma, Ewing
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Sarcoma, Myeloid
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
Scrapie
A variable concept for the preparation of branched glycosyl phosphatidyl inositol anchors.
Seizures
Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice.
Seizures
Morphological changes among hippocampal dentate granule cells exposed to early kindling-epileptogenesis.
Severe Combined Immunodeficiency
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Severe Combined Immunodeficiency
Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood.
Skin Diseases
Differentiation of human T lymphocytes: II. Phenotypic difference in skin and blood malignant T-cells in cutaneous T-cell lymphoma.
Skin Diseases
Thy-1 and T-cell receptor antigen expression in mycosis fungoides and benign inflammatory dermatoses.
Soft Tissue Infections
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Spinal Cord Compression
Transgenic overexpression of the cell adhesion molecule L1 in neurons facilitates recovery after mouse spinal cord injury.
Spinal Dysraphism
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Spinal Dysraphism
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes.
Spinal Dysraphism
New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy?
Spinal Dysraphism
The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population.
Spinal Dysraphism
Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida.
Squamous Cell Carcinoma of Head and Neck
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate.
Squamous Cell Carcinoma of Head and Neck
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Staphylococcal Infections
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Starvation
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
Starvation
Delayed processing of dihydrofolate reductase heterogeneous nuclear RNA in amino acid-starved mouse fibroblasts.
Starvation
Folate deficiency followed by ionizing radiation perturbs hepatic dihydrofolate reducatse activity.
Starvation
Multiple transcription start sites, DNase I-hypersensitive sites, and an opposite-strand exon in the 5' region of the CHO dhfr gene.
Starvation
Relationship between the expression of estrogen-regulated genes and estrogen-stimulated proliferation of MCF-7 mammary tumor cells.
Starvation
The role of thymine starvation in the expression of type IV plasmid-encoded trimethoprim-resistant dihydrofolate reductase.
Stomach Neoplasms
Heterogeneity of methotrexate binding in human colon tumor cells.
Stomach Neoplasms
THY-1 (CD90) expression promotes the growth of gastric cancer cells.
Stomatitis
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Stroke
A comprehensive association analysis between homocysteine metabolic pathway gene methylation and ischemic stroke in a Chinese hypertensive population.
Stroke
Common mutations at the homocysteine metabolism pathway and pediatric stroke.
Stroke
Translocation of a long amino-terminal domain through ER membrane by following signal-anchor sequence.
Synucleinopathies
Alpha-Synuclein-induced DNA Methylation and Gene Expression in Microglia.
Synucleinopathies
Impact of DHA intake in a mouse model of synucleinopathy.
Teratocarcinoma
Suppression of the hypomethylated Moloney leukemia virus genome in undifferentiated teratocarcinoma cells and inefficiency of transformation by a bacterial gene under control of the long terminal repeat.
Teratocarcinoma
[Transformation of the cells of transplantable teratocarcinoma CBA9H6 by a bacterial dihydrofolate reductase gene]
Teratoma
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Testicular Neoplasms
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Tetanus
Characterization of isolated mouse cerebellar cell populations in vitro.
Tetanus
Expression of Thy-1, H-2, and NS-4 cell surface antigens and tetanus toxin receptors in early postnatal and adult mouse cerebellum.
Tetanus
Further evidence for the presence of subepithelial nerve cells in the rat ileum--an immunohistochemical study.
Tetanus
Maintenance of immunocytologically identified Purkinje cells from mouse cerebellum in monolayer culture.
Tetanus
Neuronal differentiation of cloned human teratoma cells in response to retinoic acid in vitro.
Thrombosis
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis.
Thymoma
A cDNA construct of tissue inhibitor of metalloproteinases (TIMP) linked to the last exon of Thy-1 confers glycophospholipid anchorage on this naturally secreted protein.
Thymoma
Alloantigenic phenotype of radiation-induced thymomas in the mouse.
Thymoma
Cell-specific heterogeneity in sensitivity of phosphatidylinositol-anchored membrane antigens to release by phospholipase C.
Thymoma
Glycolipid anchors are attached to Thy-1 glycoprotein rapidly after translation.
Thymoma
Identification of defects in glycosylphosphatidylinositol anchor biosynthesis in the Thy-1 expression mutants.
Thymoma
Indomethacin-induced sialic acid-mediated changes in surface markers from "cortical type" to "medullary type" in murine thymoma line EL-4.
Thymoma
Mechanism of catecholamine-mediated destabilization of messenger RNA encoding Thy-1 protein in T-lineage cells.
Thymoma
No glycolipid anchors are added to Thy-1 glycoprotein in Thy-1-negative mutant thymoma cells of four different complementation classes.
Thymoma
Recombinant glycosyl-phosphatidylinositol-anchored proteins are not associated with protein kinases in transfected thymoma cells.
Thymoma
Removal of lymphocyte surface molecules with phosphatidylinositol-specific phospholipase C: effects on mitogen responses and evidence that ThB and certain Qa antigens are membrane-anchored via phosphatidylinositol.
Thymoma
Susceptibility to cell death is a dominant phenotype: triggering of activation-driven T-cell death independent of the T-cell antigen receptor complex.
Thymoma
Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites.
Thymoma
Thy-1 mRNA destabilization by norepinephrine requires a 3' UTR cAMP responsive decay element and involves RNA binding proteins.
Thymoma
Thy-1-negative and Ly-1-negative variants of T cells produce interleukin 2 in response to mitogens.
Thymoma
Thy-L antigen expression on rat brain cell lines.
Thymoma
Transformation of undifferentiated Thy-1lo B220+ thymic lymphoid cells by the Abelson murine leukemia virus.
Thymoma
Two different mutants blocked in synthesis of dolichol-phosphoryl-mannose do not add glycophospholipid anchors to membrane proteins: quantitative correction of the phenotype of a CHO cell mutant with tunicamycin.
Thymus Neoplasms
Stage-specific induction of terminal deoxynucleotidyl transferase in a T-lymphoid line upon coculture with a thymic stromal line.
Thymus Neoplasms
The programmed cell death of an immature thymocyte cell line transgenic for an alpha beta TCR and the c-myc proto-oncogene.
Thyrotoxicosis
Cytoenzymologic activities of some oxidroeductases and alkaline phosphatase of leucocytes in Basedow, Cushing and Addison diseases.
Thyrotoxicosis
Immunoexpressions of embryonic and nonembryonic stem cell markers (Nanog, Thy-1, c-kit) and cellular connections (connexin 43 and occludin) on testicular tissue in thyrotoxicosis rat model.
Toxoplasmosis
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Toxoplasmosis
Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design.
Toxoplasmosis
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
Toxoplasmosis
Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.
Toxoplasmosis
Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
Toxoplasmosis
Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice.
Toxoplasmosis
Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.
Toxoplasmosis
Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
Toxoplasmosis
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Toxoplasmosis
Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii.
Toxoplasmosis
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation.
Toxoplasmosis
Targeting DHFR in parasitic protozoa.
Toxoplasmosis
The cytogenetic effects of pyrimethamine on male mouse germ cells.
Toxoplasmosis, Cerebral
Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.
Toxoplasmosis, Cerebral
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Toxoplasmosis, Congenital
Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis.
Trypanosomiasis
Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate.
Trypanosomiasis, African
Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors.
Trypanosomiasis, African
Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase.
Trypanosomiasis, African
Trypanosomal Dihydrofolate Reductase Reveals Natural Antifolate Resistance.
Tuberculosis
1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
Tuberculosis
A proposed model of Mycobacterium avium complex dihydrofolate reductase and its utility for drug design.
Tuberculosis
Antifolate Activity of Plant Polyphenols against Mycobacterium tuberculosis.
Tuberculosis
Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
Tuberculosis
Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase.
Tuberculosis
Crystal structures of the closed form of Mycobacterium tuberculosis dihydrofolate reductase in complex with dihydrofolate and antifolates.
Tuberculosis
Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors.
Tuberculosis
Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors.
Tuberculosis
Detection of Pneumocystis carinii in a rat model of infection by polymerase chain reaction.
Tuberculosis
E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
Tuberculosis
Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
Tuberculosis
Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Tuberculosis
High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.
Tuberculosis
Identification of novel DHFR inhibitors for treatment of tuberculosis by combining virtual screening with in vitro activity assay.
Tuberculosis
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Tuberculosis
Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Tuberculosis
In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Tuberculosis
Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
Tuberculosis
Kinetic and Chemical Mechanism of the Dihydrofolate Reductase from Mycobacterium tuberculosis.
Tuberculosis
Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
Tuberculosis
Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Tuberculosis
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
Tuberculosis
Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Tuberculosis
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Tuberculosis
para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
Tuberculosis
Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F420H2-dependent reduction.
Tuberculosis
Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Tuberculosis
Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.
Tuberculosis
Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.
Tuberculosis
Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
Tuberculosis
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
Tuberculosis
Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.
Tuberculosis
Structural and Dynamics Perspectives on the Binding of Substrate and Inhibitors in Mycobacterium tuberculosis DHFR.
Tuberculosis
Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Tuberculosis
Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
Tuberculosis
Sulfonamide derivatives as Mycobacterium tuberculosis inhibitors: in silico approach.
Tuberculosis
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
Tuberculosis
Synthesis of 6-(4-(4-propoxyphenyl) piperazin-1-yl)-9H-purine derivatives as antimycobacterial and antifungal agents: In-vitro evaluation and in-silico study.
Tuberculosis
The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
Tuberculosis
Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Tuberculosis
Trade-offs with stability modulate innate and mutationally acquired drug resistance in bacterial dihydrofolate reductase enzymes.
Tuberculosis
Two Parallel Pathways in the Kinetic Sequence of the Dihydrofolate Reductase from Mycobacterium tuberculosis.
Tuberculosis
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Tuberculosis
Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
Tuberculosis
[Characterization of Mycobacterium tuberculosis dihydrofolate reductase immobilized on magnetic nanoparticles].
Urinary Bladder Neoplasms
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
Urinary Bladder Neoplasms
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.
Urinary Bladder Neoplasms
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets.
Urinary Bladder Neoplasms
[Expression of human-mouse chimeric antibody ch-BD1 and its affinity to human bladder cancer in vitro and in vivo]
Urinary Bladder Neoplasms
[Significantly improvement of antibody expression level in CHO cells through downregulation of the DHFR gene in expression vector]
Urinary Tract Infections
Characterization of trimethoprim resistant E. coli dihydrofolate reductase mutants by mass spectrometry and inhibition by propargyl-linked antifolates.
Urinary Tract Infections
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
Uterine Cervical Neoplasms
Designing Dihydrofolate Reductase Inhibitors as X-ray Radiosensitizers to Reverse Radioresistance of Cervical Cancer.
Vaccinia
Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Vaccinia
Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Varicose Ulcer
Effect of the GPI anchor of human Thy-1 on antibody recognition and function.
Vesicular Stomatitis
Specific selection of host cell glycoproteins during assembly of murine leukaemia virus and vesicular stomatitis virus: presence of Thy-1 glycoprotein and absence of H-2, Pgp-1 and T-200 glycoproteins on the envelopes of these virus particles.
Vesicular Stomatitis
Tolerance by selective in vivo expansion of foreign major histocompatibility complex-transduced autologous bone marrow.
Virus Diseases
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Virus Diseases
Functional expression of influenza A viral nucleoprotein in cells transformed with cloned DNA.
Virus Diseases
Peyer's patches in murine AIDS: dissociation between lymphoproliferation and anergy.
Virus Diseases
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Vitamin B 12 Deficiency
Folate, folic acid and 5-methyltetrahydrofolate are not the same thing.
Vitamin B 12 Deficiency
Vitamin B12--folate interrelations.
Whooping Cough
Rapid induction of Thy-1 antigenic markers on keratinocytes and epidermal immune cells in the skin of mice following topical treatment with common preservatives used in topical medications and in foods.
Wilms Tumor
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Xeroderma Pigmentosum
Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines.
Xeroderma Pigmentosum
DNA repair in man.
Xeroderma Pigmentosum
Mutational analysis of a function of xeroderma pigmentosum group A (XPA) protein in strand-specific DNA repair.
Xeroderma Pigmentosum
Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.5.1.3 dihydrofolate reductase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
